Novel Aerosol Formulation Containing A Polar Fluorinated Molecule

专利摘要:
The present invention relates to stable pharmaceutical formulations for inhalation use. Formulations include active substances, aerosol propellants, polar fluorinated molecules and excipients. Preferred propellants are HFA 134a or HFS 227 or mixtures thereof.
公开号:KR20030025265A
申请号:KR10-2003-7000349
申请日:2001-07-10
公开日:2003-03-28
发明作者:필리페 로구에다
申请人:아스트라제네카 아베；
IPC主号:

专利说明:

Novel Aerosol Formulation Containing A Polar Fluorinated Molecule
[2] Pressurized metered dose inhalers (pMDIs) are known in the art. Old problems with pMDIs containing suspension formulations include creaming of the suspension, coarse drug suspension, drug aggregation and adhesion to the dispersing apparatus.
[3] It has surprisingly been found that these problems can be solved by novel pharmaceutical preparations containing polar fluorinated molecules with suitable excipients. The formulations of the present invention result in improved aerosol drug suspension characteristics, ie, increase in phase separation time (creaming or precipitation), generation of microsuspensions, reduction of particle adhesion to can walls and inhibition of particle aggregation.
[1] The present invention relates to pharmaceutical aerosol formulations for the administration of pharmaceutically active substances by inhalation.
[4] Brief description of the drawings
[5] 1-58 show photographs of attachment to samples prepared for Examples and Controls as follows.
[6]
[7] Detailed description of the invention
[8] Accordingly, a first aspect of the present invention provides a pharmaceutical formulation comprising a drug, an aerosol propellant, an excipient that is soluble among polar fluorinated molecules and polar fluorinated molecules.
[9] Suitable drugs that can be used in the formulations of the invention include all drugs that can be administered by inhalation route, such as steroids, peptides, oligonucleotides, small organic molecules, etc., in particular those administered with pMDI. Such drugs are not limited to those that treat respiratory diseases, and include those suitable for nasal delivery and spray delivery.
[10] In a preferred embodiment, the present invention provides dispersions suitable for pulmonary or nasal delivery of one or more bioactive molecules for local or systemic administration, including fluorinated molecules and excipients in propellants or propellant mixtures.
[11] The bioactive drug can be selected from any therapeutic or diagnostic agent. For example, it may be allergic drugs, bronchodilators, bronchoconstrictors, lung lung surface active agents, analgesics, antibiotics, leukotriene inhibitors or antagonists, anticholinergic drugs, mast cell inhibitors, antihistamines, anti-inflammatory agents, antitumor agents, anesthetics, Tuberculosis drugs, imaging drugs, cardiovascular agents, enzymes, steroids, genetic material, viral vectors, antisense drugs, proteins, peptides and combinations thereof.
[12] Examples of specific drugs that may be formulated according to the present invention include mometasone, ifpratropium bromide, tiotropium and salts thereof, salemeterol, fluticasone propionate, beclomethasone dipropio Nate, Reproterol, Clenbuterol, Ropleponide and its salts, Nedochromil, Sodium Chromoglycate, Flunisolid, Bunesonide, Formoterol Fumarate Dihydrate, Symbicoat ™ (Budesonide and Formo) Terrol), Biozan ™, 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl] ethylamino] -N- [2- [2- (4 -Methylphenyl) ethoxy) ethyl] propanesulfonamide, terbutalin, terbutalin sulfate, salbutamol base and sulfate, phenoterol, 3- [2- (4-hydroxy-2-oxo-3H- 1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl) ethoxy] ethyl] propanesulfonamide, hydrochloride. All such compounds may be in free base form or in pharmaceutically acceptable salts known in the art.
[13] Suitable aerosol propellants are those known in the art, for example 1,1,1,2-tetrafluoroethane (P134a) or 1,1,1,2,3,3,3-heptafluoropropane Hydrogen fluoride alkane propellant, including (P227). Preferred propellants include P134a or P227 or mixtures of P134a and P227, in particular density balanced mixtures of these two materials.
[14] Suitable polarized fluorinated molecules include those commercially available from companies such as Apollo chemicals and Fluorochem. Preferably, polar fluorinated molecules are pharmaceutically acceptable, non-toxic and non-irritating. Fluorinated molecules of suitable polarity should be capable of admixing in the propellant in sufficient amounts and capable of dissolving excipients. Although solids are also possible, the fluorinated molecules are preferably liquid at room temperature. Preferably, the polar fluorinated molecule has a straight, preferably short carbon chain. Most preferably, the polar fluorinated molecule contains oxygen functional groups, i.e. fluorinated alcohols, ethers, carboxylic acids, esters, aldehydes and ketones, amines and mixtures thereof, and any other fluorinated compounds having functional groups based on oxygen. Have
[15] Suitable examples of polar fluorinated molecules include the following:
[16] n-butyl pentafluoropropionate, ethyl perfluoro n-dodecanoate, fluorineert (FC-75), 2,2,3,3,3 pentafluoropropyl methyl ether, methyl perfluorodecanoate 8, 2H perfluoro 5,8,11-trimethyl-3,6,9,12-tetrafluoropropylether, fluoride (FC-430), 1,1,2,2, tetrafluoroethyl 2, 2,3,3 tetrafluoropropylether, 1H, 1H, 2H, 2H perfluorooctan-1-ol, 4,4,4 trifluorobutan-1-ol, pomblin (MF 402), pomblin (ZDOL), perfluoroheptanoic anhydride, methyl perfluoro 2,5,8,11-tetramethyl 3,6,9,12, tetraoxapentadecanoate, N, N-diethyl-2,3 , 3,3 tetrafluoropropionamide, ethyl 11H-perfluorodecanoate, lH, lH, 2H, 3H, 3H perfluoro-1,2-nonanediol, 1H, 1H, perfluorononan-1 -Ol, alflunox (606,1406,2507,6008,14013), allyl heptafluorobutyrate, allyl heptafluoro Sopropyl ether, allyl 1,1,2,3,3,3-hexafluoropropyl ether, allyl perfluoroheptanoate, allyl perfluorooctanoate, allyl 1H, 1H perfluorooctyl ether, allyl Perfluoropentanoate, 4-amino-2,2-difluorobutyric acid, 2-amino-3-fluorobutyric acid, 4-amino-2-fluorobutyric acid, 2-amino-4-iminoheptafluoro Lopent-2-ene, 2-amino-4,4,4-trifluorobutyric acid, 3-amino-4,4,4-trifluorobutyric acid, 1,1 bis (diethylamino) tetrafluoro- 1-propene, bis (heptafluoroisopropyl) ketone, bis (hexafluoroisopropyl) maleate, bis (hexafluoroisopropyl) itaconate, bis [2-iodine-3 (perfluorooctyl ) Propyl adipate, bis (perfluorooctyl) itaconate, bis (perfluorooctyl) maleate, bis (2,2,2-trifluoroethyl) itaconate, bis (2,2,2 -T Lifluoroethyl) maleate, 1H, 1H-2,5 bis (trifluoromethyl) -3,6-dioxadecafluorononanol, 3,3-bis (trifluoromethyl) -3- Hydroxypropionic acid, 2,2 bis (trifluoromethyl) propionic acid, n-butyl-1,1,2,2-tetrafluoroethyl ether, n-butyl trifluoroacetate, tert-butyl trifluoroacetate, 1,1,1,5,5,6,6,7,7,7-decafluoro-2,4-heptanedione, 1H, lH, 6H-decfluorohexan-1-ol, 2H, 3H deca Fluoropentane, diethyl difluoromalonate, 2,2-difluoroethanol, 2,2-difluoroethyl acetate, 2,2-difluoroethylamine, DL-4,4-difluoro Glutamic acid, 2,2-difluoromalonamide, difluoromethyl, 2,2,3,3,3-pentafluoropropyl ether, difluoromethyl 2,2,2-trifluoroethyl ether, di Fluoromethyl 2,2,2-trifluoroethyl ether, 1,3-difluoro-2-propanol, dimethyl, hexaflu Gluglutarate, dimethyl octafluoroadipate, dimethyl perfluoroazelate, dimethyl perfluoro-1,10-decanedicarboxylate, dimethyl perfluorosebacate, dimethyl perfluorosuberate, dimethyl tetra Fluorosuccinate, dimethyl 2,2,2-trifluoropropionyl carbinol, 4-ethoxy-1,1,2-trifluorobut-1-ene, ethyl 3-amino-4,4,4 -Trifluorocrotonate, ethyl ethoxymethylene-3-oxo-4,4,4-trifluorobutyrate, ethyl 4-fluoro-3-methyl-2-pentenoate, ethyl 2-fluoropropio Nate, ethyl heptafluorobutyrate, ethyl heptafluorobutyryl acetate, ethyl 3-hydroxy-4,4,4-trifluorobutyrate, ethyl 2-methyl-3-hydroxy-4,4,4-tri Fluorobutyrate, ethyl pentafluoropropionate, ethyl perfluoroheptanoate, ethyl perfluoro- n-dodecanoate (including all compounds such as CnF ₂ n + 1C0 ₂ CH ₂ CH ₃ , n = 4-16 (possibly some H substitution in CF chain, and double bond)), ethyl perfluoro-n -Dodecanoate, ethyl 7H-perfluoroheptanoate, ethyl perfluorononanoate, ethyl 9H-perfluorononanoate, ethyl perfluorooctanoate, ethyl perfluoropentanoate, ethyl 5H-perfluoropentanoate, ethyl 11H-perfluorodecanoate, ethyl 1,1,2,2-tetrafluoroethylether, ethyl 4,4,4-trifluorobutyrate, ethyl 3- ( Trifluoromethyl) crotonate, ethyl 4,4,4-trifluoro-3- (trifluoromethyl) crotonate, fluorineert (FC40, FC430, FC70, FC71, FC72, FC77, FC84, FC87, FC104, FC6001, FC6003), DL-2-fluoro-3-alanine, 2-fluoroethanol, D-erythro-4-fluoroglutamic acid, 2-fluoroethyl methacrylate , DL-4-fluoroglutamic acid, L-erythro-4-fluoroglutamic acid, D-threo-4-fluoroglutamic acid, DL-threo-4, fluoroglutamic acid, L-threo-4-fluoroglutamic acid, DL-erythro-4-fluoroflutamine, L-erythro-4-fluoroglutamine, DL-threo-4-fluoroglutamine, DL-erythro-4-fluoroisoglutamine, L-erythro-4-fluoro Isoglutamine, DL-Threo-4-fluoroisoglutamine, 3-fluoro-DL-norleucine, Flutec (PP1, PP2, PP3, PP9, PP10, PP11, PP25, PP50), Pomblene (M, Y (L-Vac), Y (H-Vac), Z15, MF402, ZDOL), Galden (HT70, HT85, HT90, HT100, HT110, HT135, HT200, HT230, HT250, HT270), 1H, 1H Heptafluorobutane -1-ol, 1H, 1H-heptafluorobutyl acetate, heptafluorobutyramid, heptafluorobutyric acid, heptafluorobutyric anhydride, 4,4,5,5,6,6,6-heptafluoro Hexanoic acid, 4,4,5,5,6,6,6 heptafluorohexan-1-ol, 4,4,5,5,6,6,6-hep Fluorohex-2-en-1-ol, heptafluoroisopropyl methyl ether, 1,1,1,3,5,5,5-heptafluoropentane-2,4-dione, heptafluoropenta- 2-ol, 2-heptafluoropropoxy-2,3,3,3-tetrafluoropropane-1-ol, heptafluoropropyl methyl ether, heptafluoropropyl 1,2,2,2-tetrafluoro Low ethyl ether, heptafluoropropyl trifluorovinyl ether, 2,2,3,4,4,4-hexafluorobutan-1-ol, 2,2,3,3,4,4-hexafluoro Butan-1-ol, 2,2,3,4,4,4-hexafluorobutyl difluoromethyl ether, 2,2,3,4,4,4-hexafluorobutyl methacrylate, hexafluoro Gluglutaramide, hexafluoroglutaric acid, hexafluoroisopropanol, 1,1,1,3,3,3-hexafluoroisopropyl acrylate, mono-hexafluoroisopropyl itaconate, mono- Hexafluoroisopropyl maleate, 1,1,1,3,3,3-hexafluoroisopropyl meta Relate, isopropyl urethane hexafluoro isopropyl ether, hexafluoro -N- methacrylate, hexafluoro-leucine, 2-methyl-hexafluoroisopropanol; Hexafluoro-1,5-pentanediol, 3,3,4,5,5,5-hexafluoropentan-2-ol, 1,1,2,3,3,3-hexafluoropropyl ethyl ether , 1,1,2,3,3,3-hexafluoropropyl methyl ether, 4,4,4,6,6,6-hexafluoro-4- (trifluoromethyl) hexan-1-ol, 4,5,5,6,6,6-hexafluoro4- (trifluoromethyl) hex-2-enoic acid, 4,5,5,6,6,6-hexafluoro-4- (tri Fluoromethyl) hex-2-en-1-ol, hexafluoro-DL-valine, isopropyl trifluoroacetate, N, methylbis (heptafluorobutyramid), methyl heptafluorobutyrate, methyl hepta Fluoropropyl ketone, methyl 2,2,3,3,4,4-hexafluorobutyrate, methyl 2-hydroxy-2- (trifluoromethyl) phen-4-enoate, N-methyl-N, Methoxytrifluoroacetamide, methyl nonafluorobutyl ether, methyl nonafluorobutyl ketone, methyl 2,2,3,3,4,4,5,5-octafluoropentanoate, methyl pentafluoro But-3-enoate, methyl pentafluoropropionate, methyl pentafluoropropionyl acetate, methyl perfluorodecanoate, methyl perfluorododecanoate, methyl perfluoroheptanoate, methyl 7H- Perfluoroheptanoate, methyl perfluorohexadecanoate, methyl perfluoro (2-methyl-3-oxahexanoate), methyl perfluorononanoate, methyl perfluorooctadecanoate, Methyl perfluoropentadecanoate, methyl perfluorotetradecanoate, methyl perfluoro-2,5,8,11-tetramethyl-3,6,9,12-tetraoxapentadecanoate, methyl Perfluorotridecanoate, methyl perfluorodecanoate, methyl 2,3,3,3-tetrafluoropropionate, methyl trifluoroacetate, methyl 4,4,4-trifluoroacetoacetate, 2-methyl-4,4,4-trifluorobutanol, Methyl 4,4,4-trifluorocrotonate, methyl 2- (trifluoromethyl), 3,3,3-trifluoropropionate, methyl trifluoropropenoate, methyl trifluoropyruvate , (Nonnafluoro-n-butyl) epoxide, 2- (nonnafluorobutyl) ethyl acrylate, 2- (nonnafluorobutyl) ethyl methacrylate, 6- (nonnafluorobutyl) hexanol, 3 -(Nonnafluorobutyl) -2-hydroxypropyl acrylate, 3- (nonnafluoro-n-butyl) prop-2-enol, 3- (nonnafluoro-n-butyl) 1,2-pro Phenoxide, 1H, 1H, 2H, 2H-nonafluorohexan-1-ol, 1H, 1H-nonafluoropentan-1-ol, 2,2,3,3,4,4,5,5-octa Fluoro-1,6-hexanediol, 2,2,3,3,4,4,5,5-octafluorohexane-1,6-diacrylate, 2,2,3,3,4,4 , 5,5-octafluorohexane-1,6-dimethacrylate, 3,3,4,4,5,5,6,6-octafluoro-1,8-octanediol, 1H, 1H, 1H-octafluoropenta-1-ol, 2,2,3,3,4,4,5,5-octaflu Rho-1,6-hexanediol, 1,1,1,2,2-pentafluorobutan-2-ol, 1,1,1,2,2-pentafluoro-6,6-dimethyl-3, 5-heptadione, 6- (pentafluoroethyl) hexane-l-ol, 4,4,5,5,5-pentafluoropentane-l-ol, 2,2,3,3,3-pentafluoro Lopropan-1-ol, pentafluoropropionaldehyde hydrate, pentafluoropropionaldehyde
[17] Methyl hemiacetal, pentafluoropropionamide, 2,2,3,3,3-pentafluoropropyl acrylate, 2,2,3,3,3-pentafluoropropyl methacrylate, 2,2,3 , 3,3-pentafluoropropyl methyl ether, 2,2,3,3,3-pentafluoropropyl 1,1,2,2-tetrafluoroethyl ether, 1H, lH, l0H, 10H-perfluoro Rho-1,10-decanediol, 1H, 1H-perfluorodecane-1-ol, 1H, 1H, 2H, 2H-perfluorodecane-1-ol, 1H, lH, 2H, 2H-perfluoro Decanthiol, 1H, lH, 2H, 2H-perfluorodecyl acrylate, lH, lH, 2H, 2H-perfluorodecyl methacrylate, 3- (perfluoro-n-decyl) prop-2- Enol, 3- (perfluoro-n-decyl) -1,2-propenoxide, 1H, 1H-perfluoro- (3,7-dimethyloctan-1-ol), 2H-perfluoro- ( 5,8-dimethyl-3,6,9-trioxadodecane), 1H, lH, 12H, 12H-perfluoro-1,12-dodecanediol, 1H, lH-perfluorododecane
[18] -l-ol, 1H, lH, 2H, 2H-perfluorododecane-l-ol, 1H, 1H, 2H, 2H-perfluorododecyl acrylate, 1H, 1H, 2H, 2H-perfluorodode Sil methacrylate, 7H-perfluoroheptanal, 7H-perfluoro-1,1-heptanediol, perfluoroheptanoic anhydride, lH, 1H-perfluoroheptan-1-ol, 1H, lH, 7H-perfluoroheptan-1-ol, perfluoroheptoxypoly (propyloxy) acrylate, perfluoroheptoxypoly (propyloxy) methacrylate, 1H, 1H, 7H-perfluoroheptyl methacryl Late, 1H, 1H-perfluorohexadecane-1-ol, 3 perfluorohex-2-hydroxypropyl methacrylate, 2- (perfluoro-n-hexyl) acetaldehyde dimethyl acetal, 3- Perfluorohexyl-2-hydroxypropyl acrylate, 3-perfluorohexyl-2-hydroxypropyl methacrylate, 3- (perfluorohexyl) propan-1-ol, 3- (perfluoro- n-hexyl) prop-2-enol, 3- (perfluoro-n-hexyl) -1, 2-prop Noxide, 11- (perfluoro-n-hexyl) undecanol, 11 (perfluoro-n-hexyl) undec-10-enol, 6, (perfluoroisopropyl) hexane-l-ol, 3 -(Perfluoro-3-methylbutyl) -2-hydroxy propyl acrylate, 3- (perfluoro-3-methylbutyl) -2-hydroxy propyl methacrylate, lH, lH, 2H, 2H- Perfluoro-9-methyldecane-l-ol, 2- (perfluoro-9-methyldecyl) ethyl acrylate, 2H-perfluoro-5-methyl-3,6-dioxanonane, 1H, 1H , 2H, 2H-perfluoro-11-methyldodecane-1-ol, perfluoro- (2-methylhept-3-en-5-one), 1H, 1H, 2H, 2H-perfluoro- 5-methylhexan-1-ol, 2- (perfluoro-5-methylhexyl) ethyl acrylate, 2- (perfluoro-5methylhexyl) ethyl methacrylate-3- (perfluoro-5- Methylhexyl) -2-hydroxypropyl acrylate, 3- (perfluoro-5-methylhexyl)
[19] 2-hydroxypropyl methacrylate, 1H, 1H, 2H, 2H-perfluoro-7-methyloctan-1-ol, 2- (perfluoro-7-methyloctyl) ethyl acrylate, 2- ( Perfluoro-7-methyloctyl) ethyl methacrylate, 6- (perfluoro-7-methyloctyl) hexanol, 3- (perfluoro-7-methyloctyl) -2-hydroxypropyl acrylate, 3- (perfluoro-7-methyloctyl) -2-hydroxypropyl methacrylate, 1H, lH, 2H, 3H, 3H-perfluoro-1,2-nonanediol, 1H, lH, 9H, 9H Perfluoro-1,9-nonanediol, 1H, 1H-perfluorononan-1-ol, 1H, lH, 9H-perfluorononan-1-ol, 1H, 1H, 9H perfluoronon 1-ene, 1H, lH, 9H-perfluorononyl acrylate, lH, 2H, 9H-perfluorononyl methacrylate, 1H, 1H-perfluorooctadecan-1-ol, 1H, lH, 8H , 8H-perfluoro-1,8-octanediol, n perfluorotaxane ammonium salt, lH, 1H-perfluorooctan-1-ol, 1H, 1H, 2H, 2H-perfluorooctan-1-ol , 1H, 1H, 8H-perfluorooctan-1-ol, perfluoro oct Cy-poly (isobutoxy) -2chloropropoxy-1,2-propyl diacrylate, 2- (perfluoro-n-octyl) acetaldehyde, 2- (perfluoro-n, octyl) acetaldehyde di Ethyl acetate, perfluorooctyl acrylate, 1H, lH-perfluorooctyl acrylate, lH, 1H, 2H, 2H-perfluorooctyl acrylate, 6- (perfluorooctyl) hexanol, 3- ( Perfluorooctyl) -2-hydroxypropyl acrylate, 3- (perfluorooctyl) -2-hydroxypropyl methacrylate, mono-perfluorooctyl itaconate, mono-perfluorooctyl malate , Perfluorooctyl methacrylate, 1H, lH-perfluorooctyl methacrylate, 3- (perfluorooctyl) propanol, 3- (perfluorooctyl) prop-2-enol, 11- (purple Luoro-n-octyl) undec-10-ene-l-ol, 1H, lH, 5H, 5H-perfluoropentyl-1,5-dimethacrylate, perfluoropolyether straight chain & PFO-XR75 , Perfluoroceva Lactic acid, lH, lH-perfluorotedecane-l-ol, lH, lH, 13H perfluorotridecane-l-ol, perfluoro-2-trifluoromethyl-4-oxanonane, perfluoro- (3,5,5trimethylhexano) acid, 1H, 1H-perfluoro (3,5,5-trimethylhexan-1-ol), 2H-perfluoro (5,8,11-trimethyl-3, 6,9,12-tetraoxatetradecane), 1H, lH, 2H, 3H, 3H-perfluoro-1,2-undecanediol, perfluorodecanoic acid, 1H, lH-perfluorodecane-l -Ol, 1H, 1H, 11H-perfluorodecan-1-ol, 1H, lH, 11H-perfluorodecyl acrylate, 1H, 1H, 11H-perfluorodecyl methacrylate, polyperfluor Low Ethylene Glycol Diacrylate, Polyperfluoroethylene Glycol Dimethacrylate, Sodium Heptafluorobutyrate, Sodium Pentafluoropropionate, 2,2,3,3-Tetrafluoro-1,4-butanedi Acrylate, 2,2,3,3-tetrafluoro l, 4, butanedimethacrylate, 1,1,3,3-tetrafluoro Dimethyl ether, 1,1,2,2 tetrafluoroethyl 2,2,3,3-tetrafluoropropyl ether, 1,1,2,2, tetrafluoroethyl 2,2,2-trifluoroethyl Ether, 1,1.2,2 tetrafluoroethyl 2,2,2 trifluoroethyl ether, 1,2,2,2 tetrafluoroethyl trifluoromethyl ether, 4,5,5,5-tetrafluoro -4 (heptafluoropropoxy) pentanoic acid, 4,5,5,5-tetrafluoro-4- (heptafluoropropoxy) pentan-1-ol, tetrafluorosuccinic acid, 4,5,5, 5-tetrafluoro-4- (trifluoromethoxy) pentan-1-ol, 4,5,5,5-tetrafluoro-4- (trifluoromethyl) pentan-1-ol, 4,5, 5,5-tetrafluoro-4- (trifluoromethyl) pent-2-en-1-ol, N- (N-trifluoroacetyl-L-cystenyl) glycine methyl ester, DL-3,3 , 3-trifluoro-2-alanine, 4,4,4-trifluorobutan-1-ol, 1,1,1-trifluorobutan-2-one, 4,4,4-trifluoro Butan-2-one, 4,4,4-triple Orobut-2-en-1-ol, 1,1,2-trifluoro-2-chloroethyl 2,2,2-trifluoroethyl ether, 4,4,4 trifluorocrotonamide, 4, 4,4-trifluoro-3,3-dimethoxybutanol, 2,2,2-trifluoroethanol, 2,2,2-trifluoroethylbutyrate, 1,2,2-trifluoroethyl tree Fluoromethyl ether, 1,1,1-trifluoro-2,4-hexanedione, beta-trifluoromethylcrotonic acid, DL-2- (trifluoromethyl) leucine, DL-2- (trifluoro Rhomethyl) norleucine, DL-2- (trifluoromethyl) norvaline, 2- (trifluoromethyl) propan-2-ol, 6,6,6-trifluoronorleucine, 5,5,5 -Trifluoronorvaline, 1,1,1-trifluoropropan-2-ol, 3,3,3-trifluoropropan-1-ol, 1,1,1-trifluoro-2-propyl Acetate, 4,4,4-trifluoro-3- (trifluoromethyl) butan-1-ol, 2-allyl hexafluoroisopropanol, butyl difluoroacetate, n-butyl penta Fluoropropionate, tert-butyl pentafluoropropionate, N, N-diethyl-2,3,3,3-tetrafluoropropionamide, 2,2-difluoroethyl trifluoromethyl ether , 1- (ethoxy) nonafluorobutane, 3-fluoropropan-1-ol, 3H-heptafluoro-2,2,4,4-tetrahydroxypentane, 2,2,3,3,4 , 4-hexafluoro-1,5-pentyl diacrylate, 1,1,2,3,3,3-hexafluoropropyl 2,2,2-trifluoro ethyl ether, methyl 2,2-di Fluoro-3-oxopentanoate, methyl 2, methoxytetrafluoropropionate, methyl perfluoro-2,5,8,11-tetramethyl-3,6,9,12-tetraoxapentade Decanoate, methyl 3,3,3-trifluoro-DL-lactate, 3,3,4,4,4-pentafluorobutan-2-one, pentafluorodimethyl ether, pentafluoroethyl methyl ether , 2,2,3,3,3-pentafluoropropyl trifluoromethyl ether, 2- (perfluoroalkyl) ethanol, purple Auroallylfluorosulfate, perfluoro-2,5,8,11,14,17,20-heptamethyl-3,6,9,12,15,18-hexaoxahexaenylcosanoyl fluoride, mono -Perfluorooctyl itaconate, 2H-perfluoro 5,8,11,14,17-pentamethyl-3,6,9,12,15,18-hexaoxahenic acid, perfluoropolyether di Nitrile, polyfluoropolyethyleneacrylate, polyfluoropolyethylene methacrylate, 2,2,2-trifluoroethyl trifluoromethyl ether, perfluorodecalin, perfluorooctyl bromide, di-chloro-octyl Bromide and 1H, 1H, 5H octafluoro-l-pentanol.
[20] Preferably the fluorinated polar molecules are n-butyl pentafluoropropionate, ethyl perfluoro n-dodecanoate, fluorineert (FC-75), 2,2,3,3,3 pentafluoro Propyl methyl ether, methyl perfluorodecanoate, 2H perfluoro-5,8,11-trimethyl-3,6,9,12-tetrafluoropropylether, fluoride (FC-430), 1,1 , 2,2, tetrafluoroethyl 2,2,3,3 tetrafluoropropylether, 1H, 1H, 2H, 2H perfluorooctan-1-ol, 4,4,4 trifluorobutan-1- All, Pombleline (MF 402), Pombleline (ZDOL), perfluoroheptanoic anhydride, methyl perfluoro 2,5,8,11-tetramethyl 3,6,9,12, tetraoxapentadecanoate , N, N-diethyl-2,3,3,3 tetrafluoropropionamide, ethyl 11H-perfluorodecanoate, 1H, 1H, 2H, 3H, 3H perfluoro-1,2-nonanediol , 1H, 1H, perfluorononan-l-ol or 1,1,2,2 tetrafluoroethyl 2,2,2 trifluoro Ethyl ether.
[21] More preferred fluorinated molecules include 1H, 1H, 2H, 2H perfluorooctan-1-ol and
[22] 1,1,2,2 tetrafluoroethyl 2,2,2 trifluoroethyl ether.
[23] Excipients used in the formulations are surfactants or polymers and mixtures thereof, with copolymers being particularly preferred. Excipients may be soluble or miscible in polar fluorinated molecules. Suitable excipients include the following:
[24] Acrylone 1005, Crudesta F160, Methoxy PEG Amine, Methoxy PEG Carboxymethyl, 4 Arms PEG, Cholic Acid, MYRJ 52 P, APG-810-XL, APG-1014-XL, Glucophone 215, Glucophone 600, Breeze 52, gum xanthan, salicylic acid, D-lactose monohydrate, α-lactose monohydrate, lecithin egg, carrageenan, socalan C05, Eudragit RLPO, Eudragit RSPO, Eudragit E100, Eudragit S100, Eu Dragit L100, Poly (DL-Rasid Coglycolide), Gantrez S-97 BF, Gantrez AN-119, Gantrez AN-169, Myristic acid, Poly (Lactated EO Lactide), Poly (Methyl methacrylate- (β-ethylene oxide), lactose, carboxymethyl cellulose sodium salt, 1-0-n-octyl (β D glucopyranoside, AOT DI-CF4H, dioctyl-sulfosuccinate sodium salt) (AOT), Phospholipone 100, Crudesta F10, Crudesta SL 40, APG 3399, Methoxy-PEG-DSPE MW 2000, Methoxy-PEG-DSPE MW 5000, N Dodecyl β D Maltoside, N Octyl β D Gluco Lanoside, α-cyclodextrin, β-cyclodextrin hydrate, β-cyclodextrin, γ cyclodextrin hydrate, γ cyclodextrin, γ cyclodextrin hydrate, dioxycholic acid, taurocholic acid, D mannitol, poly (methyl methacrylate ), Montanov 202, Montanov 68 EC, n dodecyl β D glucopyranoside, N decyl (βD glucopyranoside, n decyl βD maltopyranoside, glutamate DOE-120, glutate SS, gluc Lucamate SSE-20, Glucam DOE-120, Glucam P10, Glucam E20, Glucam P20 Disteared, Glucam P20, Glucat 125, Bridge 30, Bridge 96, Chrodashic LS 30, Cross-Essential L99, Copolymer VC 713, Copolymer 958, Glucopan 650 EC, α-Tocopherol, PVP K30, K25 and Plasdon K-29 / 32, PEG 600 and 1000, Tri-ammonium poly (ethylene glycol), Lactose based compounds (E.g., poly (lactide-coglycolide), lactitol, lactose, cellulite Os based compounds (eg carboxymethylcellulose, cellulose, hydroxypropyl cellulose), fatty acids (eg castor oil), PEGs and derivatives (eg star PEG), sugar compounds (eg alkyl Polyglucosides, methyl glucosides, sugar esters such as berol AG6202, glucophone compound range, montanob 68, montanob 202, grlotene LSE87, crodesta compound range, poly (ethylene oxide) compounds (eg For example, hydroxy-terminated 3-armed polyethylene oxide, hydroxy-terminated 8-armed polyethylene oxide, carboxy-terminated 8-armed polyethylene oxide, 4-armed star polyethylene oxide, poly (methyl methacrylate b-ethylene oxide), poly (t-butyl methacrylate-b-ethylene oxide), poly (lactide-ethylene oxide lactide triblock copolymer), Ω-diacrylonyl terminal Li (lactide-ethylene oxide-lactide) triblock copolymer, poly (lactone-β-ethylene oxide-β-lactone) triblock copolymer, poly (ethylene oxide-β-caprolactone), PEO-PPO copolymer Poly (ethylene oxide-β-propylene oxide), also known as poly (methylmethacrylate-β-ethylene oxide), also known as PMMA-PEO copolymer. Further examples include citric acid, dibutyl sebacate, edetic acid, glyceryl monooleate & monostearate, glycofinol, crodamol compound range, maltitol, maltodextrin, triglycerides, polymethacrylates, polyoxyethylene alkyl ethers, citric acid Sodium Dihydrate, Sorbitol, Mirage and Bridge Compound Range, Pluron Compound Range, Acrylone 1005, Fluorinated AOT, Colic Acid, Copolymer 958, Copolymer VC713, Cross Essential L99, Chrodyanic LS30, AOT sodium salt, phosphoricone 100H, salicylic acid, socalan C05, poly (lactide coglycolide), poly (ethylene-β-methyl methacrylate), poly (ethylene-β-2-vinyl pyridine), poly (Ethylene-β-4-vinyl pyridine), poly (methyl methacrylate-β-sodium acrylate), poly (methyl methacrylate-β-sodium methacrylate), PEG derivative compounds (Amino acid-PEG, carboxyl-PEG copolymer, methoxy PEG amine, methoxy PEG carboxymethyl, branched PEG 4 arm, star PEG, PEG-PLA-PEG triblock copolymer, etc.), sugar branched cyclodextrin derivatives , PEO cyclo derivatives, and dendrimer-PEO-dendrimer triblock-copolymers.
[25] Preferably, the excipient is PEG based. Preferred excipients are methoxy-PEG-DSPE
[26] MW 5000, Eudragit E100, Glucamate DOE 120, Methoxy-PEG-DSPE MW 2000, Acrylidone 1005, Chrodesta F160, Methoxy PEG Amine, Methoxy PEG Carboxymethyl, 4-Am PEG, Cholic Acid, MYRJ 52 P, APG-810-XL, APG-1014-XL, Glucophone 215, Glucophone 600, Breeze 52, Gum Xanthan, Salicylic Acid, D-Lactose Monohydrate, Lactose Monohydrate, Lecithin Egg, Carrageinine, Socalan C05, Eudragit RLPO, Eudragit RSPO, Eudragit E100, Eudragit S100, Eudragit L100, Poly (DL-Rasid Coglycolide), Gantrez S-97 BF, Gantrez AN-119, Gantrez AN-169, myristic acid, poly (lactide EO lactide), poly (methyl methacrylate-β-ethylene oxide), lactose, carboxymethyl cellulose sodium salt, 1-0-n-octyl β D Glucopyranoside, AOT DI-CF4H, Dioctyl-sulfosuccinate sodium salt (AOT), Phospholipone 100, Chrodesta F10, Chrodesta SL 40, APG 3399, Methoxy-PEG DSPE MW 2000, Me Oxy-PEG-DSPE MW 5000, N dodecyl β D maltoside, N octyl βD glucopyranoside, cyclodextrin, β cyclodextrin hydrate, β cyclodextrin, gamma cyclodextrin hydrate, gamma cyclodextrin, gamma cyclodextrin hydrate, Deoxycholic acid, taurocholic acid, D-mannitol, poly (methyl methacrylate), montanov 202, montanob 68 EC, n dodecyl βD glucopyranoside, N decyl β D glucopyranoside, n decyl βD Maltopyranoside, Glucamate DOE-120, Glucate SS, Glucamate SSE-20, Glucam DOE 120, Glucam P10, Glucam E20, Glucam P20 Disteared, Glucam P20, Glucat 125 , Breeze 30, Breeze 96, Chrodastic LS 30, Cross-energy L99, Copolymer VC 713, Copolymer 958, Glucophone 650 EC, α-tocopherol, PVP K30, K25 and Plasdon K-29 / 32, PEG 600 and 1000, 3-arm poly (ethylene glycol).
[27] Most preferably, the excipient is methoxy-PEG-DSPE MW 5000, Eudragit E100, Glucamate DOE 120 or methoxy-PEG-DSPE MW 2000.
[28] The grades of fluorinated molecules and excipients mentioned herein are purely exemplary and do not limit the scope of the invention. Preferably, the fluorinated molecules and excipients are pharmaceutically acceptable.
[29] Other ingredients such as other cosolvents, stabilizers, surfactants, lubricants, excipients, preservatives, buffers, antioxidants, sweeteners, water trapping agents, extenders and taste blockers may be included in the formulations of the present invention as desired. .
[30] The formulations of the invention can be prepared, for example, by mixing molecules of fluorinated polarity with excipients and then adding drug powder to the mixture. The propellant is then added to the drug slurry, and the formulation obtained is then subjected to any known method, for example under pressure (addition of propellant under pressure) or cold charge (addition of propellant at temperatures below the boiling point). In aliquots in defined pMDIs suitable for nasal or pulmonary drug delivery. Pharmaceutically active ingredients can be processed to obtain the desired particle size distribution or specific surface properties. For example, pharmaceutically active ingredients can be micronized by conventional methods prior to mixing, or mixtures of pharmaceutically active ingredients can be micronized by conventional methods after mixing.
[31] Suitably the concentration of fluorinated polar molecules is from 0.0001 to 55% w / w, more preferably from 0.1 to 25%, most preferably from 0.3 to 15%. The concentration of the excipient is preferably 0.001% to 1%, preferably 0.01 to 1%.
[32] The pMDI instrument for use in the formulations of the invention preferably comprises a metal can, eg an aluminum can, sealed with a suitable metering valve. In addition, plastic and glass cans can be used. Suitable cans, coated cans such as cans coated with fluorinated polymers and metering valves are known in the art.
[33] The pharmaceutical formulations of the invention are useful for treating local and systemic diseases and may be administered, for example, via the upper and lower respiratory tract, including the nasal route. As such, the present invention also provides pharmaceutical aerosol formulations as defined herein for use in therapy; The use of a pharmaceutical aerosol formulation for use in the manufacture of a medicament for the treatment of diseases through the airways; And a method of treating a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the pharmaceutical aerosol formulation of the invention. Inflammatory diseases in the airways such as asthma, rhinitis, COPD, alveolitis, bronchiolitis and bronchitis can be treated using the pharmaceutical aerosol formulations of the invention.
[34] In addition, the pharmaceutical formulations of the present invention are useful for systemic delivery for many many non-respiratory diseases such as cancer, pain control, anesthesia, infections, vaccinations, and the like.
[35] Another aspect of the invention is to reduce the precipitation and creaming of pharmaceutical aerosol formulations and to easily prepare a very fine stable suspension comprising a hydrogen fluoride alkane propellant in which drug particles are dispersed in the hydrogen fluoride alkane propellant. For the use of polar fluorinated molecules in admixture with excipients.
[36] A further aspect of the invention provides the pharmaceutical aerosols described herein for use in therapy. In addition, the present invention provides a method of treatment comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical aerosol formulation as described herein. In particular, the present invention provides methods for treating asthma, rhinitis and COPD.
[37] The invention will be illustrated by the following non-limiting examples.
[38] Selection of Examples
[39] A series of tests was conducted to select new formulations of formulation. In order to select suitable fluorinated compounds, their solubility and mixing in propellants HFA 134a and HFA 227 were tested (which fluorinated additives are required beforehand to play a suitable role in the formulation). The solubility of the selected excipients was then tested in one of the fluorinated liquids (1H, 1H, 2H, 2H perfluorooctan-1-ol, abbreviated 4HOFOH). Finally 9 excipients (methoxy-PEG-DSPE MW 2000, methoxy-PEG-DSPE MW 5000, glucate DOE 120, kolic acid, APG 3399, AOT DI-HCF ₆ , 10 n octyl βD glycopyrano Said, 4-arm PEG, and Eudragit E100) were tested in fluorinated liquids that could be mixed in the propellant.
[40] The results of this study are reported in the following sections. The photograph of attachment is shown in the figure.
[41] 2.1 Mixing and Solubility of Fluorinated Molecules in Propellants
[42] In order for fluorinated compounds to be useful in novel aerosol formulations, they must preferably be completely mixed or dissolved in the propellant at the required concentration. This also means mixing thoroughly in the mixture of propellants.
[43] The fluorinated compound was weighed in a clean PET bottle. The bottle was then shrunk and then pressurized with one of the propellants until the desired total weight was reached.
[44] The mixing and solubility of HFA 227 and 134a are listed in Table 1. The values in parentheses indicate the concentration when the test is complete. Thus, at concentrations below these limits the solution is single phase. The concentrations quoted are not upper limits. It is sufficiently possible that at higher concentrations the fluorinated compound can be mixed or dissolved. For fluorinated compounds (C = 9.09% w / w), the liquid was found to be insoluble at 9.09% w / w. However, this does not exclude that it can be mixed at lower concentrations and is therefore also useful for the purposes of the present invention.
[45] TABLE 1 Mixing or Solubility of Fluorinated Molecules in Propellants
[46]
[47] Molecules listed in the compound list and not shown in the following table show the same degree of solubility as other compounds and are therefore not included in this Example section. However, they can still be used within the scope of the present invention in the low concentration range and are not excluded as potential systems.
[48] 2.2 Solubility of Selected Excipients in 4HPFOH
[49] A second test was performed to assess the solubility (or mixing for liquid samples) of some excipients in 4HPFOH.
[50] The excipients were weighed in a glass bottle locked with a plastic cap. 4HPFOH was added to the required concentration, the bottle was sealed with Teflon tape and locked with a cap. The sample was sonicated and heated to accelerate solubilization of the excipient. The bottle was then allowed to cool. Observations were then performed to evaluate their solubility (see Table 2 for results).
[51] 2.3 Solubility of Excipients in Some Ranges in Fluorinated Systems
[52] The last test performed to determine the appropriate list of excipients was to evaluate the solubility of some of the preceding excipients in a mixed or soluble fluorinated liquid. Methoxy PEG-DSPE MW 2000, Methoxy-PEG-DSPE MW 5000, Glucamate DOE 120, Eudragit E100, Cholic Acid, APG 3399, DI-HCF6, 1 O n Octyl βD Glycopyranoside And 4 cancer PEG.
[53] The excipients in the glass bottles were weighed, the fluorinated liquid was added by weight, and the bottles were sealed with Teflon Tate and Tightening Cap to measure solubility. The sample was then heated, sonicated and cooled to accelerate dissolution. The cooled sample was visually observed. The concentration of the solution was 1% w / w (unless stated otherwise). Thus, compounds reported to be insoluble may be insoluble at 1% w / w, but have low solubility. The choice of the 1% w / w limit is arbitrary.
[54] Observations of solubility are listed in Tables 3, 4 and 5 below. Soluble compounds can be used as excipients in novel formulations. For example, in the case of methoxy-PEG-DSPE MW 2000, five fluorinated molecules can be used with excipients at concentrations of 1% w / w or higher, and at other concentrations three different fluorinated molecules can be used. have.
[55] TABLE 2 Solubility of excipients selected from 4HPFOH
[56]
[57] TABLE 3 Solubility of excipients in 1% w / w fluorinated systems
[58] Methoxy-PEG DSPE MW 2000Methoxy-PEG DSPE MW 5000Glucamate DOE 120 Fluorideno Yes Yes 1,1,2,2-tetrafluoroethyl 2,2,3,3 tetrafluoropropyl ether Yes Yes Yes Pomblin MD 402 Yes on Yes Pomblin ZDOL Yes Yes Yes Perfluoroheptanoic anhydrideno Yes Yes Methyl perfluoro 2,5,9,11-tetramethyl 3,6,9,12 tetraoxapentadecanoate Yesno Yes N, N-diethyl-2,3,3,3-tetrafluoropropionamidenono Yes 1,1,2,2 tetrafluoroethyl 2,2,2 trifluoroethyl ether Yes Yes Yes
[59] TABLE 4 Solubility of excipients in 1% w / w fluorinated systems (unless otherwise stated)
[60] Kolic acidAPG 3399DI-HCF ₆Fluoridenono Yes 1,1,2,2-tetrafluoroethyl 2,2,3,3 tetrafluoropropyl ethernonono Pomblin MD 402nono Yes Pomblin ZDOLnonono Perfluoroheptanoic anhydride Yes Yes Yes Methyl perfluoro 2,5,9,11-tetramethyl 3,6,9,12 tetraoxapentadecanoateYesno Yes N, N-diethyl-2,3,3,3-tetrafluoropropionamidenono Yes 1,1,2,2 tetrafluoroethyl 2,2,2 trifluoroethyl ethernono Yes (0.1% w / w)
[61] TABLE 5 Solubility of excipients in fluorinated systems at 1% w / w
[62] 1 O n Octyl βD Glycopyranoside4 cancer PEGEudragit E100 Fluoridenonono 1,1,2,2-tetrafluoroethyl 2,2,3,3 tetrafluoropropyl etherDo not test Yes Yes Pomblin MD 402 Yes Yes Yes Pomblin ZDOL Yes Yes Yes Perfluoroheptanoic anhydride Yes Yes Yes Methyl perfluoro 2,5,9,11-tetramethyl 3,6,9,12 tetraoxapentadecanoateno Yesno N, N-diethyl-2,3,3,3-tetrafluoropropionamideno Yes Yes 1,1,2,2 tetrafluoroethyl 2,2,2 trifluoroethyl etherno Yes Yes
[63] From the above results, it is possible to devise suitable excipient formulations which form new formulations.
[64] 3 Selected Embodiments
[65] 3.1 List of Examples and Controls
[66] From the results in the table, more than 29 new agents can be considered, and many more can be devised from the list of compounds. The following formulations were specially evaluated:
[67] 1-HFA 227 with methoxy-PEG-DSPE MW 5000 and 4HPF0H and budesonide
[68] 2-degree methoxy-PEG-DSPE MW 5000 and 4HPF0H and budesonide in HFA 134a
[69] 3-Methoxy-PEG-DSPE MW 5000 and 4HPF0H and formoterol fumarate dihydrate in HFA 227
[70] 4-methoxy-PEG-DSPE MW 5000 and 4HPF0H and formoterol fumarate dihydrate in HFA 134a
[71] Eudragit E100 and 4HPFOH with Budesonide in 5-HFA 227
[72] Glucamate DOE 120 and 4HPFOH with budesonide in 6-HFA 227
[73] 7-HFA 227 with methoxy-PEG-DSPE MW 2000 and 4HPFOH and budesonide
[74] Methoxy-PEG-DSPE MW 2000 and 4HPFOH and formoterol fumarate dihydrate in 8-HFA 227
[75] Methoxy-PEG-DSPE MW 2000 and 4HPFOH with terbutaline sulfate in 9-HFA 227
[76] 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N with methoxy-PEG-DSPE MW 2000 and 4HPFOH in 10-HFA 227 -[2- [2- (4-methylphenyl) ethoxy) ethyl] propanesulfonamide
[77] Glucamate DOE 120 and 1,1,2,2 tetrafluoroethyl 2,2,2 trifluoroethyl ether and formoterol fumarate dihydrate in 11-HFA 227
[78] A range of control samples were prepared for direct comparison with new formulations, which were as follows:
[79] 1-formoterol fumarate dihydrate in HFA 227
[80] Formoterol fumarate dihydrate in 2-HFA 134a
[81] PEG 1000 and PVP K25 and formoterol fumarate dihydrate in a mixture of 3-HFA 227 and 134a
[82] 4- terbutaline sulfate in HFA 227
[83] 5-terbutaline sulfate in HFA 134a
[84] 6- PEG 600 and PVP K30 and terbutaline sulfate in HFA 227
[85] 7- budesonide in HFA 227
[86] 8- budesonide in HFA 134a
[87] 9- PEG 1000 and PVP K25 and budesonide in HFA 227
[88] 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl in 10-HFA 227 ) Ethoxy) ethyl] propanesulfonamide
[89] 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl in 11-HFA 134a ) Ethoxy) ethyl] propanesulfonamide
[90] PEG 600 and PVP K30 in 12-HFA 227 with 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [ 2- (4-methylphenyl) ethoxy) ethyl] propanesulfonamide
[91] All drug substances used were micronized.
[92] 3.2 Sample Manufacturing
[93] Samples for adhesion and creaming tests were prepared in clean PET bottles equipped with continuous valves. Excipients and fluorinated molecules were mixed and the drug was weighed and bottled. Thereafter, a mixture of fluorinated molecules and excipients was added to the drug. After the continuous valve was retracted by hand, the propellant was delivered at the desired weight under pressure through the valve. The samples were ultrasonically pulverized for at least 15 minutes and left to equilibrate for up to 12 hours, then observed. The samples were then evaluated and placed under standard test conditions.
[94] Samples for size measurements were prepared in a 12 ml aluminum can in a similar manner. Thereafter, the cans were drilled and the contents were transferred into the weighing vessel.
[95] 3.3 Sample Concentration
[96] Example concentrations are as follows.
[97] Example 1
[98] Budesonide: 0.125% w / w
[99] Methoxy-PEG-DSPE MW 5000: 0.320% w / w
[100] 4HPFOH: 31.7% w / w
[101] HFA 227: to be 100% w / w
[102] Example 2
[103] Budesonide: 0.174% w / w
[104] Methoxy-PEG-DSPE MW 5000: 0.286% w / w
[105] 4HPFOH: 28.4% w / w
[106] HFA 134a: to be 100% w / w
[107] Example 3
[108] Formoterol fumarate dihydrate: 0.154% w / w
[109] Methoxy-PEG-DSPE MW 5000: 0.320% w / w
[110] 4HPFOH: 32.2% w / w
[111] HFA 227: to be 100% w / w
[112] Example 4
[113] Formoterol fumarate dihydrate: 0.220% w / w
[114] Methoxy-PEG-DSPE MW 5000: 0.317% w / w
[115] 4HPFOH: 31.5% w / w
[116] HFA 134a: to be 100% w / w
[117] Example 5
[118] Six suspensions were prepared.
[119]
[120] Example 6
[121] Six suspensions were prepared.
[122]
[123] Example 7
[124] Six suspensions were prepared.
[125]
[126] Example 8
[127] Six suspensions were prepared.
[128]
[129] Example 9
[130] Six suspensions were prepared.
[131]
[132] Example 10
[133] Six suspensions were prepared.
[134]
[135] Example 11
[136] Six suspensions were prepared.
[137]
[138] Control 1
[139] Formoterol fumarate dihydrate: 0.0167% w / w
[140] HFA 227: to be 100% w / w
[141] Control 2
[142] Formoterol fumarate dihydrate: 0.0167% w / w
[143] HFA 134a: to be 100% w / w
[144] Control 3
[145] Formoterol fumarate dihydrate: 0.0167% w / w
[146] PEG 1000: 0.1% w / w
[147] PVP K25: 0.001% w / w
[148] HFA 227: 25% w / w
[149] HFA 134a: to be 100% w / w
[150] Control 4
[151] Terbutaline sulfate: 0.300% w / w
[152] HFA 227: to be 100% w / w
[153] Control 5
[154] Terbutaline sulfate: 0.3% w / w
[155] HFA 134a: to be 100% w / w
[156] Control 6
[157] Terbutaline sulfate: 0.299% w / w
[158] PEG 600: 0.03% w / w
[159] PVP K30: 0.005% w / w
[160] HFA 227: to be 100% w / w
[161] Control 7
[162] Budesonide: 0.260% w / w
[163] HFA 227: to be 100% w / w
[164] Control 8
[165] Budesonide: 0.259% w / w
[166] HFA 134a: to be 100% w / w
[167] Control 9
[168] Budesonide: 0.259% w / w
[169] PEG 1000: 0.3% w / w
[170] PVP K25: 0.001% w / w
[171] HFA 227: to be 100% w / w
[172] Control 10
[173] 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl) ethoxy) ethyl Propanesulfonamide: 0.427% w / w
[174] HFA 227: to be 100% w / w
[175] Control 11
[176] 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl) ethoxy) ethyl Propanesulfonamide: 0.428% w / w
[177] HFA 134a: to be 100% w / w
[178] Control 12
[179] 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl) ethoxy) ethyl Propanesulfonamide: 0.428% w / w
[180] PEG 600: 0.3% w / w
[181] PVP K30: 0.0025% w / w
[182] HFA 227: to be 100% w / w
[183] Evaluation of 4 Examples
[184] The new formulations are particularly useful for reducing drug adhesion to can walls, reducing phase separation time and keeping the suspension finely dispersed. Thus, three tests were performed: evaluation of adhesion to the can walls, evaluation of creaming or electrification and sizing of the dispersion. These results were compared with the characteristics of the control sample.
[185] 4.1 Evaluation of Drug Adhesion
[186] Evaluation of drug attachment to can walls was performed visually and recorded with a digital camera. Samples prepared in PET bottles were observed after several days of storage. These were stirred to allow the creamed or precipitated layer to redisperse. Note that at this stage, samples made with HFA 227 may be creamed and show some drug attachment, whereas samples made with HFA 134a tend to settle because they show very low adhesion in the headspace. It is important. PET bottles are offset against a black background and in some cases stabilized before taking a picture. The level of drug attachment can be seen on the circle across the bottle. The absence of a ring means no adhesion. Attachment photos can be found in the drawings for samples in the prepared range. Reference photos and control samples were contrasted with the figures.
[187] The picture is strong evidence of the benefits of the new formulation. Two types of drug attachments may be listed. First, in the head space attachment, the particles are spread out over the entire head space area (eg control 6). Next, the attachment at the propellant-gas interface will be named ring adhesion (eg Example 7.4). In all controls, there were two types of attachment. However, among the new formulations, the first type of attachment disappeared except for 5.6, 7.2, 10.2 and 10.6. Even in these cases, the extent was significantly reduced. Ring attachment is present for some examples but very faint (eg 7.2 and 7.4).
[188] Samples made with HDA 134a were on average better than those made with HFA 227. As mentioned earlier, this is mainly due to the density difference. If the particles are not present at the interface and wet in the liquid, they will not adhere to the head space and will form a dry ring or surface coating.
[189] It is also interesting to note that for the 134a sample, the new formulation forms a milky suspension, ie a fine suspension, as compared to the control which tends to be rough (see particles in Controls 2 and 3 of the Examples). In addition, the novel formulation is more stable than the control as can be seen from the milky appearance of most examples. The creaming time of these samples was longer than the time it took to set up the bottle and take pictures (~ several minutes). This was not the case for many controls.
[190] Budesonide Examples 1, 2, 5, 6 and 7 should be compared to Control 7, 8 and 9 (Budedesonide samples). In all examples, the new formulations dramatically reduce the amount of drug attachment to the can walls. In all cases except Examples 5.6 and 7.2, there was no visible drug on the can walls. Even for Examples 5.6 and 7.2, adhesion was much less than that of the control sample. Small rings of particles were sometimes seen on the can walls, but even in this case they were very small compared to the control.
[191] Formoterol fumarate dihydrate Examples 3, 4, 8 and 11 should be compared to Controls 1, 2 and 3. Terbutalin sulfate examples in series 9 should be compared to controls 4, 5, and 6. 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl) in series 10 Oxy) ethyl] propanesulfonamide Examples should be compared to controls 10, 11 and 12. All these systems showed a sharply improved performance over each control sample, similar to that described for budesonide.
[192] 4.2 Evaluation of Phase Separation Kinetics of New Formulations
[193] Phase separation kinetics of the new formulations were assessed visually and using OSCAR technology (optical suspension characteristics). The OSCAR technique records the turbidity of a sample at two different heights as a function of time. Samples can be studied in situ in clean PET bottles.
[194] Photographs of selected samples were taken at intervals to provide evidence of slow phase separation kinetics. Samples prepared in HFA 227 were creamed, but samples prepared in HFA 134a precipitated due to the difference in density between particles and propellant.
[195] Drug suspensions without stabilizer added may take a few seconds to several minutes until complete destabilization. However, new formulations take longer to separate phases. It takes an average of several hours to form a separate solid layer. This is a significant improvement over the performance of other HFA formulations and is one of the important advantages of this novel formulation.
[196] Examples 1, 2, 3 and 4 were studied with OSCAR technology. In all four cases, the onset of detectable creaming occurred over 1 hour and 30 minutes. For Example 4, it exceeds 3 hours. This is in excess of the time scale generally observed in other agents, especially control samples (with creaming occurring within minutes).
[197] Other examples were visually studied. Immediately after stirring and 1 hour after stirring, photographs were recorded for all samples. Photographs entitled “After Stirring” should be understood to be taken within 1 minute to 1 minute 30 seconds after stirring of the first bottle of the series. The system was stable for one hour, well maintained beyond its limits, and in some cases extended to several days. However, the control sample has very reduced stability and on average creams within 30 minutes after stirring. The level of instability was dependent on the additive concentration. All suspensions had improved stability properties at concentrations in the range studied.
[198] 4.3 Evaluation of Powder Level of New Formulations
[199] Selected new formulations were sized here using Mastersizer X to demonstrate no aggregation. The Master Sizer X is a laser light diffraction sizing instrument developed by Malvern. The pressure cell assembly was adjusted to allow suspension size measurements in propellants. Samples were prepared in a 12 ml aluminum can equipped with a continuous valve as described above in the creaming and attachment section. Thereafter, these cans were drilled and the contents were loaded into the measurement chamber for the intended can puncher. Four drugs, formoterol fumarate dihydrate, budesonide, terbutaline sulfate and 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) Ethylamino] -N- [2- [2- (4-methylphenyl) ethoxy) ethyl] propanesulfonamide was studied. All drugs were micronized. These were formulated using methoxy-PEG-DSPE MW 2000 and 4HPFH in HFA 227. The size of formoterol fumarate dihydrate was measured in glucamate DOE-120 and 1,1,2,2-tetrafuloethyl-2,2,2-trifuloethyl ether in HFA 227. The results could then be compared with the results of the size measurements of the same drug in the reference HFA formulation. Size measurements are summarized in the table below.
[200] Formoterol fumarate dihydrate sample
[201] Formoterol fumarate dihydrate was sized in two examples of novel formulations. The first is based on the combination of methoxy-PEG-DSPE MW 2000 and 4HPFOH in HFA 227. The second is based on the combination of glucamate DOE-120 and 1,1,2,2-tetrafuloethyl-2,2,2-trifluoroethyl ether in HFA 227. The HFA formulation used for reference was based on a mixture of PEG 1000 and PVP K25 in HFA 134a and HFA 227 blends. Processing of the sizing data was done using Mie's theory. The refractive index value required in the US theory was either known (first novel formulation) or one estimated from pure propellant values (second novel formulation and reference HFA formulation). Experimental concentrations are listed in Table 6.1, The results of the size measurements are listed in Table 6.2.
[202] Table 6.1 Concentration of Formoterol Fumarate Dihydrate (FFD) Sized by Masterizer X
[203] First new formulationSecond new formulationReference HFA Formulations Methoxy-PEG-DSPEMW 2000- 0.171% w / w4HPFOH- 3.053% w / wFFD- 0.0174% w / w HFA 227 to 100% w / wGlucamateDOE-120-1.25% w / w 1,1,2,2-tetrafluoroethyl-2,2,2-trifluoroethyl ether-21.3% w / wFFD-0.049% w / wHFA 227 with% w / wPEG 1000-0.099% w / w to PVP K25-0.00099% w / w to FFF-0.0167% w / w to HFA 134a-75.12% w / w to HFA 227-24.77% w / w
[204] TABLE 6.2 Size measurement results of reference HFA formulations and new formulations of formoterol fumarate dihydrate (FFD)
[205] SampleD (v, 0.1)D (v, 0.5)D (v, 0.9)D [4,3]D [3,2]peakspan First new formulation1.272.23.522.351.93One1.022 Second new formulation0.902.525.242.861.76One1.725 Reference HFA Formulations3.999.95116.235.58.49211.28
[206] The size is expressed in μm. Span is [D (v, 0.9) -D (v, 0.1)] / D (v, 0.5).
[207] Size measurement results show that the micronized FFD in one of the two new formulations has a narrower size distribution than in the reference HFA formulation, and the particles have a smaller average size. This is because the new formulation particles can be present as individual particles and not as agglomerates. In addition, the new formulations are simple dispersion. This will have some impact on the performance of the pMDI, and it is also expected that the dosage outside the valve will be finer. Finely dispersed suspensions are good labels for effective suspending agents. The suspension is well and truly stabilized by the added excipients.
[208] Budesonide samples
[209] Two budesonide formulations were sized. The new formulation is based on the combination of methoxy-PEG-DSPE MW 2000 and 4HPFOH in HFA 227. Reference samples were prepared using PEG 1000 and PVP K25 in HFA 227. Processing of the sizing data was measured using the US theory. The refractive index values required for the theory were either known (new formulations) or one estimated from pure propellant values (reference formulations). The experimental concentrations are listed in Table 7.1 and the results of size measurements are listed in Table 7.2.
[210] Table 7.1 Concentration of Budesonide Sized by Master Sizer X
[211] New formulationReference HFA Formulations Methoxy-PEG-DSPE MW 2000- 0.173% w / w 4 HPFOH-3.095% w / w Budesonide-0.253% w / w HFA 227 to 100% w / wPEG 1000-0.299% w / w PVP K25-0.001% w / w Budesonide-0.256% w / w HFA 227 to 10 0% w / w
[212] TABLE 7.2 Size measurement results of reference HFA formulations and novel formulations of budesonide. The size is expressed in μm
[213] SampleD (v, 0.1)D (v, 0.5)D (v, 0.9)D [4,3]D [3,2]peakspan New formulation0.532.133.682.201.30One1.479 Reference HFA Formulations7.3333.587.541.715.1One2.395
[214] Span is [D (v, 0.9) -D (v, 0.1)] / D (v, 0.5).
[215] For FFD, the sizing results show that the micronized budesonide formulated in the new formulation has a narrower size distribution in the reference formulation, the particles have a smaller average size, and the size distribution is monodisperse.
[216] Terbutalin Sulfate Sample
[217] Two terbutaline sulfate samples were sized. The new formulation is based on the combination of methoxy-PEG-DSPE MW 2000 and 4HPFOH in HFA 227. Reference samples were prepared using a mixture of PEG 600 and PVP K30 in HFA 227. Modeling of sizing data was measured using US theory. The refractive index values required for the US theory were either known (new formulations) or estimated from pure propellant values (reference formulations). The experimental concentrations are listed in Table 8.1 and the results of the size measurements are listed in Table 8.2.
[218] Table 8.1 Concentrations of Terbutaline Sulfate Samples Sized by Master Sizer X
[219] New formulationReference HFA Formulations Methoxy-PEG-DSPE MW 2000- 0.1743% w / w 4 HPFOH-3.1126% w / w Terbutaline sulfate-0.0831% w / w HFA 227 to 100% w / wPEG 600-0.03% w / w PVP K30-0.005% w / w Terbutaline sulfate-0.0612% w / w HFA 227 to 100% w / w
[220] Table 8.2 Size measurement results of reference HFA formulations and novel formulations of terbutaline sulfate
[221] SampleD (v, 0.1)D (v, 0.5)D (v, 0.9)D [4,3]D [3,2]peakspan New formulation1.463.962.734.532.73One1.696 Reference HFA Formulations5.6813.640.423.110.6One2.543
[222] The size is expressed in μm. Span is [D (v, 0.9) -D (v, 0.1)] / D (v, 0.5).
[223] For FFD and budesonide, the sizing results indicate that the undifferentiated terbutalin sulfate formulated in the new formulation has a narrower size distribution in the reference formulation, the particles are concentrated at a smaller average size, and the size distribution is simple dispersion. Shows that
[224] 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl) ethoxy) ethyl Propanesulfonamide Sample
[225] To two kinds of 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl) Oxy) ethyl] propanesulfonamide samples were sized. The new formulation was based on the combination of methoxy-PEG-DSPE MW 2000 and 4HPFOH in HFA 227. Reference samples were prepared using a mixture of PEG 600 and PVP K30 in HFA 227. Modeling of sizing data was measured using US theory. The refractive index values required for the US theory were either known (new formulations) or estimated from pure propellant values (reference formulations). The experimental concentrations are listed in Table 9.1 and the results of size measurements are listed in Table 9.2.
[226] Table 9.1 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- as measured by the master sizer X Concentration of [2- (4-methylphenyl) ethoxy) ethyl] propanesulfonamide
[227] New formulationReference HFA Formulations Methoxy-PEG-DSPE MW 2000- 0.1743% w / w 4 HPFOH- 3.1126% w / w 3-[2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino ] -N- [2- [2- (4-methylphenyl) ethoxy) ethyl] propanesulfonamide-0.0831% w / w HFA 227 to 100% w / wPEG 600- 0.02941% w / w PVP K30- 0.0025% w / w3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [ 2- [2- (4-methylphenyl) ethoxy) ethyl] propanesulfonamide-0.1009% w / w HFA 227 to 100% w / w
[228] Table 9.2 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl) Size Measurement Results of Reference HFA Formulations and New Formulations of Ethoxy) ethyl] propanesulfonamide
[229] SampleD (v, 0.1)D (v, 0.5)D (v, 0.9)D [4,3]D [3,2]peakspan New formulation1.533.1439.910.62.76212.23 Reference HFA Formulations5.922.2136.342.112.925.860
[230] The size is expressed in μm. Span is [D (v, 0.9) -D (v, 0.1)] / D (v, 0.5).
[231] For FFD, budesonide, and terbutalin sulphate, the results of sizing were determined using micronized 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazole-7 formulated in a new formulation. -Yl) ethylamino] -N- [2- [2- (4-methylphenyl) ethoxy) ethyl] propanesulfonamide shows a narrower size distribution than the reference formulation and the particles have a smaller average size . In this case, the size distribution has two peaks, but due to the approximation of the imaginary part of the median refractive index, the peak is concentrated at 90 μm and may not be representative of the sample. It is this shoulder peak that results in a high span value. Despite these results, the size distribution is still narrower and smaller than in the reference formulation.
[232] 4.4 Additional Tests: Solubility of Drug Compounds in New Formulations
[233] The present invention relates to the formulation of pMDI suspensions, but does not exclude the possibility of formulation of solutions. Although most drug compounds are insoluble in fluorinated systems, it is possible to solubilize the drug in certain cases. Solubility tests were performed on four different drugs in 4HPFOH: formoterol fumarate dihydrate, budesonide, terbutalin sulfate and 3- [2- (4-hydroxy-2-oxo-3H-1, 3-benzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl) ethoxy) ethyl] propanesulfonamide.
[234] Drug suspensions were prepared in parts by weight in sealed glass bottles. The suspension was then allowed to stand for several days until equilibrium was reached. They were first evaluated optically and, for possible solubility, by UV-vis spectroscopy. The solution was then filtered through a 0.2 μm PTFE filter and studied by UV-vis spectroscopy between 280 nm and 350 nm. A range of suspensions were prepared to reach saturation levels. The absorbance was then plotted as a function of concentration to draw a calibration curve. The inflection point at which the slope of the calibration curve changes is taken as the solubility limit. Three or more experiments were performed for each drug.
[235] Formoterol fumarate dihydrate, terbutaline sulfate and 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [ 2- [2- (4-methylphenyl) ethoxy) ethyl] propanesulfonamide is insoluble in 4HPFOH. Suspensions of the drug were optically observed at C = 0.1 ppm (w / w). At this concentration, the particles were visible in the bulk solution. Thus, their respective solubility was less than 0.1 ppm (w / w). That is, the compound can be considered to be insoluble. However, budesonide is dissolved in 4HPFOH. Its solubility limit measured by UV-vis spectroscopy is 0.219% w / w to 0.246% w / w.
[236] 4.5 Additional Tests: Solubility of Drug Compounds in New Formulations
[237] The solubility of formoterol fumarate dihydrate and budesonide in 4HPFOH was tested and compared with its solubility in ethanol.
[238] Four solutions were prepared in glass bottles sealed with Teflon tape: formoterol in 4HPFOH, formoterol in ethanol, budesonide in 4HPFOH and budesonide in ethanol. The concentration of formoterol solution was 0.792% w / w in 4HPFOF and 1.365% w / w in ethanol. The concentration of budesonide solution was 0.9315% w / w in 4HPFOF and 1.215% w / w in ethanol.
[239] After three weeks of storage, the total impurity level> 0.01% in the formoterol solution was 0.782% for ethanol solution and 0.245% in 4HPFOH. For budesonide, the impurity level was 0.23% w / w in ethanol and 0.14% w / w in 4HPFOH.
[240] Impurities result from the decomposition of drug molecules in pure solvents. Thus, the concentration of impurities in the fluorinated system was less than three times that in ethanol. Thus, drug compounds are more stable in novel formulations than other pMDI formulations using cosolvents. This is another distinct advantage of this novel formulation.

权利要求:
Claims (18)
[1" claim-type="Currently amended] Pharmaceutical formulations comprising drugs, aerosol propellants, polar fluorinated molecules and excipients.
[2" claim-type="Currently amended] The pharmaceutical aerosol formulation of claim 1 for administration via pulmonary or nasal passages.
[3" claim-type="Currently amended] The drug according to claim 1 or 2, wherein the drug is an allergic drug, a bronchodilator, a bronchial contractor, a lung lung surface active agent, an analgesic agent, an antibiotic, a leukotriene inhibitor or an antagonist, an anticholine drug, a mast cell inhibitor, an antihistamine, an anti-inflammatory Pharmaceutical aerosol formulations selected from the group consisting of antitumor agents, anesthetics, tuberculosis drugs, imaging drugs, cardiovascular agents, enzymes, steroids, genetic material, viral vectors, antisense drugs, proteins, peptides and mixtures thereof.
[4" claim-type="Currently amended] The drug according to any one of claims 1 to 3, wherein the drug is bunesonide, formoterol, symbicoat ™ (budesonide and formoterol), biozan ™, 3- [2- (4-hydroxy-2 -Oxo-3H-1,3-benzothiazol-7-yl] ethylamino] -N- [2--2- (4-methylphenyl) ethoxy) ethyl] propanesulfonamide, terbutalin, salbutamol Base and sulfate, phenoterol or 3- [2- (4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl) ethylamino] -N- [2- [2- ( A pharmaceutical aerosol formulation selected from 4-methylphenyl) ethoxy] ethyl] propanesulfonamide and pharmaceutically acceptable salts thereof.
[5" claim-type="Currently amended] The pharmaceutical aerosol formulation according to any of claims 1 to 4, wherein the propellant is a fluorinated molecule.
[6" claim-type="Currently amended] 6. The pharmaceutical aerosol formulation according to claim 1, wherein the propellant is HFA 134a or HFA 227 or a mixture of HFA 134a and HFA 227. 7.
[7" claim-type="Currently amended] The pharmaceutical aerosol formulation according to any one of claims 1 to 6, wherein the polar fluorinated molecule is liquid at room temperature.
[8" claim-type="Currently amended] The pharmaceutical aerosol formulation according to any one of claims 1 to 7, wherein the polar fluorinated molecule is selected from the group:
n-butyl pentafluoropropionate, ethyl perfluoro n-dodecanoate, fluorineert (FC-75), 2,2,3,3,3 pentafluoropropyl methyl ether, methyl perfluorodecanoate 8, 2H perfluoro 5,8,11-trimethyl-3,6,9,12-tetrafluoropropylether, fluoride (FC-430), 1,1,2,2, tetrafluoroethyl 2, 2,3,3 tetrafluoropropylether, 1H, 1H, 2H, 2H perfluorooctan-1-ol, 4,4,4 trifluorobutan-1-ol, pomblin (MF 402), pomblin (ZDOL), perfluoroheptanoic anhydride, methyl perfluoro 2,5,8,11-tetramethyl 3,6,9,12, tetraoxapentadecanoate, N, N-diethyl-2,3 , 3,3 tetrafluoropropionamide, ethyl 11H-perfluorodecanoate, lH, lH, 2H, 3H, 3H perfluoro-1,2-nonanediol, 1H, 1H, perfluorononan-1 -Ol, alflunox (606,1406,2507,6008,14013), allyl heptafluorobutyrate, allyl heptafluoroyi Sopropyl ether, allyl 1,1,2,3,3,3-hexafluoropropyl ether, allyl perfluoroheptanoate, allyl perfluorooctanoate, allyl 1H, 1H perfluorooctyl ether, allyl Perfluoropentanoate, 4-amino-2,2-difluorobutyric acid, 2-amino-3-fluorobutyric acid, 4-amino-2-fluorobutyric acid, 2-amino-4-iminoheptafluoro Lopent-2-ene, 2-amino-4,4,4-trifluorobutyric acid, 3-amino-4,4,4-trifluorobutyric acid, 1,1 bis (diethylamino) tetrafluoro- 1-propene, bis (heptafluoroisopropyl) ketone, bis (hexafluoroisopropyl) maleate, bis (hexafluoroisopropyl) itaconate, bis [2-iodine-3 (perfluorooctyl ) Propyl adipate, bis (perfluorooctyl) itaconate, bis (perfluorooctyl) maleate, bis (2,2,2-trifluoroethyl) itaconate, bis (2,2,2 -T Fluoroethyl) maleate, 1H, 1H-2,5 bis (trifluoromethyl) -3,6-dioxadecafluorononanol, 3,3-bis (trifluoromethyl) -3-hydrate Oxypropionic acid, 2,2 bis (trifluoromethyl) propionic acid, n-butyl-1,1,2,2-tetrafluoroethyl ether, n-butyl trifluoroacetate, tert-butyl trifluoroacetate, 1 , 1,1,5,5,6,6,7,7,7-decafluoro-2,4-heptanedione, 1H, lH, 6H-decfluorohexan-1-ol, 2H, 3H decafluoro Lofentan, diethyl difluoromalonate, 2,2-difluoroethanol, 2,2-difluoroethyl acetate, 2,2-difluoroethylamine, DL-4,4-difluoroglutamic acid , 2,2-difluoromalonamide, difluoromethyl, 2,2,3,3,3-pentafluoropropyl ether, difluoromethyl 2,2,2-trifluoroethyl ether, difluoro Romethyl 2,2,2-trifluoroethyl ether, 1,3-difluoro-2-propanol, dimethyl, hexafluoro Gluglutarate, dimethyl octafluoroadipate, dimethyl perfluoroazelate, dimethyl perfluoro-1,10-decanedicarboxylate, dimethyl perfluorosebacate, dimethyl perfluorosuberate, dimethyl tetra Fluorosuccinate, dimethyl 2,2,2-trifluoropropionyl carbinol, 4-ethoxy-1,1,2-trifluorobut-1-ene, ethyl 3-amino-4,4,4 -Trifluorocrotonate, ethyl ethoxymethylene-3-oxo-4,4,4-trifluorobutyrate, ethyl 4-fluoro-3-methyl-2-pentenoate, ethyl 2-fluoropropio Nate, ethyl heptafluorobutyrate, ethyl heptafluorobutyryl acetate, ethyl 3-hydroxy-4,4,4-trifluorobutyrate, ethyl 2-methyl-3-hydroxy-4,4,4-tri Fluorobutyrate, ethyl pentafluoropropionate, ethyl perfluoroheptanoate, ethyl perfluoro-n Dodecanoate (including all compounds such as CnF ₂ n + 1C0 ₂ CH ₂ CH ₃ , n = 4 to 16 (possibly some H substitution in CF chain, and double bond)), ethyl perfluoro-n- Dodecanoate, ethyl 7H-perfluoroheptanoate, ethyl perfluorononanoate, ethyl 9H-perfluorononanoate, ethyl perfluorooctanoate, ethyl perfluoropentanoate, ethyl 5H -Perfluoropentanoate, ethyl 11H-perfluorodecanoate, ethyl 1,1,2,2-tetrafluoroethylether, ethyl 4,4,4-trifluorobutyrate, ethyl 3- (tri Fluoromethyl) crotonate, ethyl 4,4,4-trifluoro-3- (trifluoromethyl) crotonate, fluorineert (FC40, FC430, FC70, FC71, FC72, FC77, FC84, FC87 , FC104, FC6001, FC6003), DL-2-fluoro-3-alanine, 2-fluoroethanol, D-erythro-4-fluoroglutamic acid, 2-fluoroethyl methacrylate , DL-4-fluoroglutamic acid, L-erythro-4-fluoroglutamic acid, D-threo-4-fluoroglutamic acid, DL-threo-4, fluoroglutamic acid, L-threo-4-fluoroglutamic acid, DL Erythro-4-fluoroflutamine, L-erythro-4-fluoroglutamine, DL-threo-4-fluoroglutamine, DL-erythro-4-fluoroisoglutamine, L-erythro-4-fluoroiso Glutamine, DL-Threo-4-fluoroisoglutamine, 3-fluoro-DL-norleucine, Flutec (PP1, PP2, PP3, PP9, PP10, PP11, PP25, PP50), Pomblin (M, Y ( L-Vac), Y (H-Vac), Z15, MF402, ZDOL), Galden (HT70, HT85, HT90, HT100, HT110, HT135, HT200, HT230, HT250, HT270), 1H, 1H Heptafluorobutane- 1-ol, 1H, 1H-heptafluorobutyl acetate, heptafluorobutyramid, heptafluorobutyric acid, heptafluorobutyric anhydride, 4,4,5,5,6,6,6-heptafluorohexa Noric acid, 4,4,5,5,6,6,6 heptafluorohexan-1-ol, 4,4,5,5,6,6,6-hepta Fluorohex-2-en-1-ol, heptafluoroisopropyl methyl ether, 1,1,1,3,5,5,5-heptafluoropentane-2,4-dione, heptafluoropenta- 2-ol, 2-heptafluoropropoxy-2,3,3,3-tetrafluoropropane-1-ol, heptafluoropropyl methyl ether, heptafluoropropyl 1,2,2,2-tetrafluoro Low ethyl ether, heptafluoropropyl trifluorovinyl ether, 2,2,3,4,4,4-hexafluorobutan-1-ol, 2,2,3,3,4,4-hexafluoro Butan-1-ol, 2,2,3,4,4,4-hexafluorobutyl difluoromethyl ether, 2,2,3,4,4,4-hexafluorobutyl methacrylate, hexafluoro Gluglutaramide, hexafluoroglutaric acid, hexafluoroisopropanol, 1,1,1,3,3,3-hexafluoroisopropyl acrylate, mono-hexafluoroisopropyl itaconate, mono- Hexafluoroisopropyl maleate, 1,1,1,3,3,3-hexafluoroisopropyl metak Relate, hexafluoroisopropyl methyl ether, hexafluoroisopropylurethane-N-ethyl methacrylate, hexafluoroleucine, hexafluoro-2-methylisopropanol; Hexafluoro-1,5-pentanediol, 3,3,4,5,5,5-hexafluoropentan-2-ol, 1,1,2,3,3,3-hexafluoropropyl ethyl ether , 1,1,2,3,3,3-hexafluoropropyl methyl ether, 4,4,4,6,6,6-hexafluoro-4- (trifluoromethyl) hexan-1-ol, 4,5,5,6,6,6-hexafluoro4- (trifluoromethyl) hex-2-enoic acid, 4,5,5,6,6,6-hexafluoro-4- (tri Fluoromethyl) hex-2-en-1-ol, hexafluoro-DL-valine, isopropyl trifluoroacetate, N, methylbis (heptafluorobutyramid), methyl heptafluorobutyrate, methyl hepta Fluoropropyl ketone, methyl 2,2,3,3,4,4-hexafluorobutyrate, methyl 2-hydroxy-2- (trifluoromethyl) phen-4-enoate, N-methyl-N, Methoxytrifluoroacetamide, methyl nonafluorobutyl ether, methyl nonafluorobutyl ketone, methyl 2,2,3,3,4,4,5,5-octafluoropentanoate, methyl pentafluoro Robut-3-enoate, methyl pentafluoropropionate, methyl pentafluoropropionyl acetate, methyl perfluorodecanoate, methyl perfluorododecanoate, methyl perfluoroheptanoate, methyl 7H Perfluoroheptanoate, methyl perfluorohexadecanoate, methyl perfluoro (2-methyl-3-oxahexanoate), methyl perfluorononanoate, methyl perfluorooctadecanoate Methyl perfluoropentadecanoate, methyl perfluorotetradecanoate, methyl perfluoro-2,5,8,11-tetramethyl-3,6,9,12-tetraoxapentadecanoate, Methyl perfluorotridecanoate, methyl perfluorodecanoate, methyl 2,3,3,3-tetrafluoropropionate, methyl trifluoroacetate, methyl 4,4,4-trifluoroacetoacetate 2-methyl-4,4,4-trifluorobutanol, Methyl 4,4,4-trifluorocrotonate, methyl 2- (trifluoromethyl), 3,3,3-trifluoropropionate, methyl trifluoropropenoate, methyl trifluoropyruvate , (Nonnafluoro-n-butyl) epoxide, 2- (nonnafluorobutyl) ethyl acrylate, 2- (nonnafluorobutyl) ethyl methacrylate, 6- (nonnafluorobutyl) hexanol, 3 -(Nonnafluorobutyl) -2-hydroxypropyl acrylate, 3- (nonnafluoro-n-butyl) prop-2-enol, 3- (nonnafluoro-n-butyl) 1,2-pro Phenoxide, 1H, 1H, 2H, 2H-nonafluorohexan-1-ol, 1H, 1H-nonafluoropentan-1-ol, 2,2,3,3,4,4,5,5-octa Fluoro-1,6-hexanediol, 2,2,3,3,4,4,5,5-octafluorohexane-1,6-diacrylate, 2,2,3,3,4,4 , 5,5-octafluorohexane-1,6-dimethacrylate, 3,3,4,4,5,5,6,6-octafluoro-1,8-octanediol, 1H, 1H, 1H-octafluoropenta-1-ol, 2,2,3,3,4,4,5,5-octaflu Oro-1,6-hexanediol, 1,1,1,2,2-pentafluorobutan-2-ol, 1,1,1,2,2-pentafluoro-6,6-dimethyl-3, 5-heptadione, 6- (pentafluoroethyl) hexane-l-ol, 4,4,5,5,5-pentafluoropentane-l-ol, 2,2,3,3,3-pentafluoro Lopropan-1-ol, pentafluoropropionaldehyde hydrate, pentafluoropropionaldehyde methyl hemiacetal, pentafluoropropionamide, 2,2,3,3,3-pentafluoropropyl acrylate, 2,2, 3,3,3-pentafluoropropyl methacrylate, 2,2,3,3,3-pentafluoropropyl methyl ether, 2,2,3,3,3-pentafluoropropyl 1,1,2 , 2-tetrafluoroethyl ether, 1H, lH, lOH, 1OH-perfluoro-1,10-decanediol, 1H, 1H-perfluorodecane-1-ol, 1H, 1H, 2H, 2H-purple Luorodecan-1-ol, 1H, lH, 2H, 2H-perfluorodecanethiol, 1H, lH, 2H, 2H-perfluorodecyl acrylate, lH, lH, 2H, 2H-perfluorodecyl meta Acrylate, 3- (perfluoro-n-decyl) prop-2- Nol, 3- (perfluoro-n-decyl) -1,2-propenoxide, 1H, 1H-perfluoro- (3,7-dimethyloctan-1-ol), 2H-perfluoro- ( 5,8-dimethyl-3,6,9-trioxadodecane), 1H, lH, 12H, 12H-perfluoro-1,12-dodecanediol, 1H, lH-perfluorododecane-l-ol , 1H, lH, 2H, 2H-perfluorododecane-l-ol, 1H, 1H, 2H, 2H-perfluorododecyl acrylate, 1H, 1H, 2H, 2H-perfluorododecyl methacrylate , 7H-perfluoroheptanal, 7H-perfluoro-1,1-heptanediol, perfluoroheptano anhydride, lH, 1H-perfluoroheptan-1-ol, 1H, lH, 7H-perfluoro Roheptan-1-ol, perfluoroheptoxypoly (propyloxy) acrylate, perfluoroheptoxypoly (propyloxy) methacrylate, 1H, 1H, 7H-perfluoroheptyl methacrylate, 1H, 1H-perfluorohexadecan-1-ol, 3 perfluorohex-2-hydroxypropyl methacrylate, 2- (perfluoro-n-hexyl) acetaldehyde dimethyl acetal, 3-perfluoro Rohexyl-2-hydroxypropyl acrylate, 3-perfluorohexyl-2-hydroxypropyl methacrylate, 3- (perfluorohexyl) propan-1-ol, 3- (perfluoro-n- Hexyl) prop-2-enol, 3- (perfluoro-n-hexyl) -1, 2-propenoxide, 11- (perfluoro-n-hexyl) undecanol, 11 (perfluoro-n -Hexyl) undec-10-enol, 6, (perfluoroisopropyl) hexane-l-ol, 3- (perfluoro-3-methylbutyl) -2-hydroxy propyl acrylate, 3- (purple Fluoro-3-methylbutyl) -2-hydroxy propylmethacrylate, lH, lH, 2H, 2H-perfluoro-9-methyldecane-l-ol, 2- (perfluoro-9-methyldecyl Ethyl acrylate, 2H-perfluoro-5-methyl-3,6-dioxanonane, 1H, 1H, 2H, 2H-perfluoro-11-methyldodecane-1-ol, perfluoro- ( 2-methylhept-3-en-5-one), 1H, 1H, 2H, 2H-perfluoro-5-methylhexan-1-ol, 2- (perfluoro-5-methylhexyl) ethyl acrylate , 2- (perfluoro-5methylhexyl) ethyl meth Rate-3- (5-methylhexyl perfluoroalkyl)
2-hydroxypropyl acrylate, 3- (perfluoro-5-methylhexyl) -2-hydroxypropyl methacrylate, 1H, 1H, 2H, 2H-perfluoro-7-methyloctane-1- Ol, 2- (perfluoro-7-methyloctyl) ethyl acrylate, 2- (perfluoro-7-methyloctyl) ethyl methacrylate, 6- (perfluoro-7-methyloctyl) hexanol, 3- (perfluoro-7-methyloctyl) -2-hydroxypropyl acrylate, 3- (perfluoro-7-methyloctyl) -2-hydroxypropyl methacrylate, 1H, lH, 2H, 3H , 3H-perfluoro-1,2-nonanediol, 1H, lH, 9H, 9H-perfluoro-1,9-nonanediol, 1H, 1H-perfluorononan-1-ol, 1H, lH, 9H-perfluorononan-1-ol, 1H, 1H, 9H perfluoronon-1-ene, 1H, lH, 9H-perfluorononyl acrylate, lH, 2H, 9H-perfluorononyl methacryl 1H, 1H-perfluorooctadecane-1-ol, 1H, lH, 8H, 8H-perfluoro-1,8-octanediol, n perfluorotaxane ammonium salt, lH, 1H-perfluorooctane -1-ol, 1H, 1H, 2H, 2H-purple Rooctan-1-ol, 1H, 1H, 8H-perfluorooctan-1-ol, perfluorooctoxy-poly (isobutoxy) -2chloropropoxy-1,2-propyl diacrylate, 2- (Perfluoro-n-octyl) acetaldehyde, 2- (perfluoro-n, octyl) acetaldehyde diethyl acetate, perfluorooctyl acrylate, 1H, lH-perfluorooctyl acrylate, lH, 1H , 2H, 2H-perfluorooctyl acrylate, 6- (perfluorooctyl) hexanol, 3- (perfluorooctyl) -2-hydroxypropyl acrylate, 3- (perfluorooctyl) -2 -Hydroxypropyl methacrylate, mono-perfluorooctyl itaconate, mono-perfluorooctyl maleate, perfluorooctyl methacrylate, 1H, lH-perfluorooctyl methacrylate, 3- ( Perfluorooctyl) propanol, 3- (perfluorooctyl) prop-2-enol, 11- (perfluoro-n-octyl) undec-10-en-l-ol, 1H, lH, 5H, 5H-perfluoropentyl-1,5-dimethacryl , Perfluoropolyether straight chain & PFO-XR75, perfluorocebacic acid, lH, lH-perfluorotetradecane-l-ol, lH, lH, 13H perfluorotridecane-l-ol, perfluoro 2-trifluoromethyl-4-oxanonane, perfluoro- (3,5,5trimethylhexano) acid, 1H, 1H-perfluoro (3,5,5-trimethylhexan-1-ol) , 2H-perfluoro (5,8,11-trimethyl-3,6,9,12-tetraoxatetradecane), 1H, lH, 2H, 3H, 3H-perfluoro-1,2-undecanediol , Perfluorodecanoic acid, 1H, lH-perfluorodecane-l-ol, 1H, 1H, 11H-perfluorodecan-1-ol, 1H, lH, 11H-perfluorodecyl acrylate, 1H , 1H, 11H-perfluorodecyl methacrylate, polyperfluoroethylene glycol diacrylate, polyperfluoroethylene glycol dimethacrylate, sodium heptafluorobutyrate, sodium pentafluoropropionate, 2 , 2,3,3-tetrafluoro-1,4-butanediacrylate, 2,2,3,3-tetra Fluoro l, 4, butanedimethacrylate, 1,1,3,3-tetrafluorodimethyl ether, 1,1,2,2 tetrafluoroethyl 2,2,3,3-tetrafluoropropyl ether , 1,1,2,2, tetrafluoroethyl 2,2,2-trifluoroethyl ether, 1,1.2,2 tetrafluoroethyl 2,2,2 trifluoroethyl ether, 1,2,2 , 2 tetrafluoroethyl trifluoromethyl ether, 4,5,5,5-tetrafluoro-4 (heptafluoropropoxy) pentanoic acid, 4,5,5,5-tetrafluoro-4- ( Heptafluoropropoxy) pentan-1-ol, tetrafluorosuccinic acid, 4,5,5,5-tetrafluoro-4- (trifluoromethoxy) pentan-1-ol, 4,5,5,5 -Tetrafluoro-4- (trifluoromethyl) pentan-1-ol, 4,5,5,5-tetrafluoro-4- (trifluoromethyl) pent-2-en-1-ol, N -(N-trifluoroacetyl-L-cysteinyl) glycine methyl ester, DL-3,3,3-trifluoro-2-alanine, 4,4,4-trifluorobutan-1-ol, 1 , 1,1-tree Luorobutan-2-one, 4,4,4-trifluorobutan-2-one, 4,4,4-trifluorobut-2-en-1-ol, 1,1,2-trifluoro R-2-chloroethyl 2,2,2-trifluoroethyl ether, 4,4,4 trifluorocrotonamide, 4,4,4-trifluoro-3,3-dimethoxybutanol, 2,2 , 2-trifluoroethanol, 2,2,2-trifluoroethylbutyrate, 1,2,2-trifluoroethyl trifluoromethyl ether, 1,1,1-trifluoro-2,4- Hexanedione, beta-trifluoromethylcrotonic acid, DL-2- (trifluoromethyl) leucine, DL-2- (trifluoromethyl) norleucine, DL-2- (trifluoromethyl) norvaline, 2- (trifluoromethyl) propan-2-ol, 6,6,6-trifluoronorleucine, 5,5,5-trifluoronorvaline, 1,1,1-trifluoropropane-2 -Ol, 3,3,3-trifluoropropan-1-ol, 1,1,1-trifluoro-2-propyl acetate, 4,4,4-trifluoro-3- (trifluoromethyl Butan-1-ol, 2-allyl hexaflu Leusopropanol, butyl difluoroacetate, n-butyl pentafluoropropionate, tert-butyl pentafluoropropionate, N, N-diethyl-2,3,3,3-tetrafluoropropionamide, 2,2-difluoroethyl trifluoromethyl ether, 1- (ethoxy) nonafluorobutane, 3-fluoropropan-1-ol, 3H-heptafluoro-2,2,4,4-tetra Hydroxypentane, 2,2,3,3,4,4-hexafluoro-1,5-pentyl diacrylate, 1,1,2,3,3,3-hexafluoropropyl 2,2,2 -Trifluoro ethyl ether, methyl 2,2-difluoro-3-oxopentanoate, methyl 2, methoxytetrafluoropropionate, methyl perfluoro-2,5,8,11-tetramethyl -3,6,9,12-tetraoxapentadecanoate, methyl 3,3,3-trifluoro-DL-lactate, 3,3,4,4,4-pentafluorobutan-2-one Pentafluorodimethyl ether, pentafluoroethyl methyl ether, 2,2,3,3,3-pentafluoropropyl Lifluoromethyl ether, 2- (perfluoroalkyl) ethanol, perfluoroallylfluorosulfate, perfluoro-2,5,8,11,14,17,20-heptamethyl-3,6, 9,12,15,18-hexaoxahexaenylcosanoyl fluoride, mono-perfluorooctyl itaconate, 2H-perfluoro 5,8,11,14,17-pentamethyl-3,6,9 , 12,15,18-hexaoxahenicoic acid, perfluoropolyether dinitrile, polyfluoropolyethyleneacrylate, polyfluoropolyethylene methacrylate, 2,2,2-trifluoroethyl trifluoromethyl ether , Perfluorodecalin, perfluorooctyl bromide, di-chloro-octyl bromide and 1H, 1H, 5H octafluoro-l-pentanol.
[9" claim-type="Currently amended] The pharmaceutical aerosol formulation according to any one of claims 1 to 8, wherein the excipient is a PEG copolymer.
[10" claim-type="Currently amended] The pharmaceutical aerosol formulation according to any one of claims 1 to 9, wherein the excipient is PEG-phospholipid.
[11" claim-type="Currently amended] The pharmaceutical aerosol formulation according to any one of claims 1 to 10, wherein the excipient is selected from the group:
Acrylone 1005, Crudesta F160, Methoxy PEG Amine, Methoxy PEG Carboxymethyl, 4 Arms PEG, Cholic Acid, MYRJ 52 P, APG-810-XL, APG-1014-XL, Glucophone 215, Glucophone 600, Breeze 52, gum xanthan, salicylic acid, D-lactose monohydrate, α-lactose monohydrate, lecithin egg, carrageenan, socalan C05, Eudragit RLPO, Eudragit RSPO, Eudragit E100, Eudragit S100, Eu Dragit L100, Poly (DL-Rasid Coglycolide), Gantrez S-97 BF, Gantrez AN-119, Gantrez AN-169, Myristic acid, Poly (Lactated EO Lactide), Poly (Methyl methacrylate- (β-ethylene oxide), lactose, carboxymethyl cellulose sodium salt, 1-0-n-octyl (β D glucopyranoside, AOT DI-CF4H, dioctyl-sulfosuccinate sodium salt) (AOT), Phospholipone 100, Crudesta F10, Crudesta SL 40, APG 3399, Methoxy-PEG-DSPE MW 2000, Methoxy-PEG-DSPE MW 5000, N Dodecyl β D Maltoside, N Octyl β D Gluco Lanoside, α-cyclodextrin, β-cyclodextrin hydrate, β-cyclodextrin, γ cyclodextrin hydrate, γ cyclodextrin, γ cyclodextrin hydrate, dioxycholic acid, taurocholic acid, D mannitol, poly (methyl methacrylate ), Montanov 202, Montanov 68 EC, n dodecyl β D glucopyranoside, N decyl (βD glucopyranoside, n decyl βD maltopyranoside, glutamate DOE-120, glutate SS, gluc Lucamate SSE-20, Glucam DOE-120, Glucam P10, Glucam E20, Glucam P20 Disteared, Glucam P20, Glucat 125, Bridge 30, Bridge 96, Chrodashic LS 30, Cross-Essential L99, Copolymer VC 713, Copolymer 958, Glucopan 650 EC, α-Tocopherol, PVP K30, K25 and Plasdon K-29 / 32, PEG 600 and 1000, Tri-ammonium poly (ethylene glycol), Lactose based compounds (E.g., poly (lactide-coglycolide), lactitol, lactose, cellulite Os based compounds (eg carboxymethylcellulose, cellulose, hydroxypropyl cellulose), fatty acids (eg castor oil), PEGs and derivatives (eg star PEG), sugar compounds (eg alkyl Polyglucosides, methyl glucosides, sugar esters such as berol AG6202, glucophone compound range, montanob 68, montanob 202, grlotene LSE87, crodesta compound range, poly (ethylene oxide) compounds (eg For example, hydroxy-terminated 3-armed polyethylene oxide, hydroxy-terminated 8-armed polyethylene oxide, carboxy-terminated 8-armed polyethylene oxide, 4-armed star polyethylene oxide, poly (methyl methacrylate b-ethylene oxide), poly (t-butyl methacrylate-b-ethylene oxide), poly (lactide-ethylene oxide lactide triblock copolymer), Ω-diacrylonyl terminal Li (lactide-ethylene oxide-lactide) triblock copolymer, poly (lactone-β-ethylene oxide-β-lactone) triblock copolymer, poly (ethylene oxide-β-caprolactone), PEO-PPO copolymer Poly (ethylene oxide-β-propylene oxide), also known as poly (methyl methacrylate-β-ethylene oxide), also known as PMMA-PEO copolymer. Further examples include citric acid, dibutyl sebacate, edetic acid, glyceryl monooleate & monostearate, glycofinol, crodamol compound range, maltitol, maltodextrin, triglycerides, polymethacrylates, polyoxyethylene alkyl ethers, citric acid Sodium Dihydrate, Sorbitol, Mirage and Bridge Compound Range, Pluron Compound Range, Acrylone 1005, Fluorinated AOT, Colic Acid, Copolymer 958, Copolymer VC713, Cross Essential L99, Chrodyanic LS30, AOT sodium salt, phosphoricone 100H, salicylic acid, socalan C05, poly (lactide coglycolide), poly (ethylene-β-methyl methacrylate), poly (ethylene-β-2-vinyl pyridine), poly (Ethylene-β-4-vinyl pyridine), poly (methyl methacrylate-β-sodium acrylate), poly (methyl methacrylate-β-sodium methacrylate), PEG derivative compounds (Amino acid-PEG, carboxyl-PEG copolymer, methoxy PEG amine, methoxy PEG carboxymethyl, branched PEG 4 arm, star PEG, PEG-PLA-PEG triblock copolymer), sugar branched cyclodextrin derivatives, PEO cyclo derivatives, and dendrimer-PEO-dendrimer triblock-copolymers. Methoxy-PEG-DSPE MW 5000, Eudragit E100, Glucamate DOE 120, Methoxy-PEG-DSPE MW 2000, Acrylidone 1005, Crodesta F160, Methoxy PEG Amine, Methoxy PEG Carboxymethyl, 4 Cancer PEG, cholic acid, MYRJ 52 P, APG-810-XL, APG-1014-XL, Glucophone 215, Glucophone 600, Breeze 52, gum xanthan, salicylic acid, D-lactose monohydrate, lactose monohydrate, lecithin egg, Carrageenan, Socalan C05, Eudragit RLPO, Eudragit RSPO, Eudragit E100, Eudragit S 100, Eudragit L100, Poly (DL-Rasid Coglycolide), Gantrez S-97 BF, Gantrez AN-119, Gantrez AN-169, myristic acid, poly (lactide EO lactide), poly (methyl methacrylate-β-ethylene oxide), lactose, carboxymethyl cellulose sodium salt, 1- 0-n-octyl β D glucopyranoside, AOT DI-CF4H, dioctyl-sulfosuccinate sodium salt (AOT), phospholipon 100, rhodesta F10, rhodesta SL 40, APG 3399, meth Toxy-P EG DSPE MW 2000, methoxy-PEG-DSPE MW 5000, N dodecyl β D maltoside, N octyl βD glucopyranoside, cyclodextrin, β cyclodextrin hydrate, β cyclodextrin, gamma cyclodextrin hydrate, gamma cyclodextrin , Gamma cyclodextrin hydrate, deoxycholic acid, taurocholic acid, D-mannitol, poly (methyl methacrylate), montanov 202, montanov 68 EC, n dodecyl βD glucopyranoside, N decyl β D gluco Lanoside, n decyl βD maltopyranoside, glutamate DOE-120, glutate SS, glutamate SSE-20, glutam DOE 120, glutam P10, glutam E20, glutam P20 disteared, glue Calm P20, Glucat 125, Breeze 30, Breeze 96, Chrodadic LS 30, Cross-energy L99, Copolymer VC 713, Copolymer 958, Glucophone 650 EC, α-tocopherol, PVP K30, K25 and Plasdon K -29/32, PEG 600 and 1000, 3-arm poly (ethylene glycol).
[12" claim-type="Currently amended] Of excipients and polar fluorinated molecules to reduce precipitation and creaming of pharmaceutical aerosol formulations and to obtain very fine stable suspensions containing hydrogen fluoride alkane propellants in which drug particles are dispersed in the hydrogen fluoride alkane propellants. Usage.
[13" claim-type="Currently amended] An aerosol can comprising a formulation according to any one of the preceding claims.
[14" claim-type="Currently amended] The aerosol can of claim 13 made of metal.
[15" claim-type="Currently amended] The aerosol can of claim 13 or 14 wherein the inner surface of the can is coated with a fluoropolymer.
[16" claim-type="Currently amended] A pharmaceutical aerosol formulation according to any one of claims 1 to 11 for treatment.
[17" claim-type="Currently amended] A pharmaceutical aerosol formulation according to any one of claims 1 to 11 for the treatment of asthma, rhinitis or COPD.
[18" claim-type="Currently amended] A method of treatment of a patient in need of treatment comprising administering a therapeutically effective amount of the pharmaceutical aerosol formulation of claim 1 to a patient in need thereof.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6178459B2|2017-08-09|Medicinal aerosol products

---

US10716753B2|2020-07-21|Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems

---

US20170224762A1|2017-08-10|Method and Formulation for Inhalation

---

US9730890B2|2017-08-15|Bronchodilating beta-agonist compositions and methods

---

RU2697862C2|2019-08-21|Inhalation pharmaceutical compositions

---

JP6214925B2|2017-10-18|Formoterol-containing aerosol composition for delivery to the lung via nebulization

---

EP1283036B1|2008-01-02|Multidosis dry powder inhaler with powder reservoir

---

EP1372608B1|2007-10-10|Medical aerosol formulations

---

CA2440010C|2012-07-10|Powder inhaler formulations

---

TWI283182B|2007-07-01|Inhalable spray dried 4-helix bundle protein powders having minimized aggregation

---

RU2120285C1|1998-10-20|Aerosol pharmaceutic composition, bottle for storage and delivery of aerosol pharmaceutic composition, method of treatment of respiratory diseases, composition preparation method

---

US9308200B2|2016-04-12|Dry powder formulation comprising a phosphodiesterase inhibitor

---

AU649702B2|1994-06-02|Aerosol drug formulations

---

FI119676B|2009-02-13|Powder for use in a dry powder inhaler

---

JP5392880B2|2014-01-22|Stable pharmaceutical solution formulation for pressurized metered dose inhalers

---

US5292499A|1994-03-08|Method of preparing medical aerosol formulations including drug dissolved in reverse micelles

---

RU2629333C2|2017-08-28|Dry powder compositions represented as particles which contain two or more active ingredients for treatment of obstructive or inflammatory diseases of respiratory ways

---

Littringer et al.2012|Spray dried mannitol carrier particles with tailored surface properties–The influence of carrier surface roughness and shape

---

TWI530301B|2016-04-21|Process for providing particles with reduced electrostatic charges

---

US20150050350A1|2015-02-19|Pharmaceutical formulations for dry powder inhalers

---

CA1326210C|1994-01-18|Nasal formulations and a process for preparation thereof

---

JP4672143B2|2011-04-20|Pharmaceutical aerosol formulation

---

DE69637288T2|2008-07-10|Beclomethasone nanoparticle dispersions containing aerosols

---

DK2629754T3|2015-01-26|Liquid pharmaceutical composition for supply of active ingredients

---

US7399528B2|2008-07-15|Powder particles with smooth surface for use in inhalation therapy

同族专利:

---

公开号 | 公开日

---

NO20030133L|2003-02-24|

---

NZ523379A|2004-06-25|

---

MXPA03000276A|2003-06-06|

---

CN1455663A|2003-11-12|

---

ZA200300075B|2004-04-05|

---

US20030194378A1|2003-10-16|

---

BR0112322A|2003-07-08|

---

AT342048T|2006-11-15|

---

IL153726D0|2003-07-06|

---

ES2273864T3|2007-05-16|

---

DK1303258T3|2007-01-22|

---

WO2002003958A1|2002-01-17|

---

JP2004502719A|2004-01-29|

---

AU7286601A|2002-01-21|

---

PT1303258E|2007-01-31|

---

EP1303258B1|2006-10-11|

---

EP1303258A1|2003-04-23|

---

AU2001272866B2|2005-08-11|

---

NO20030133D0|2003-01-10|

---

DE60123793T2|2007-09-06|

---

CA2415092A1|2002-01-17|

---

DE60123793D1|2006-11-23|

---

GB0016876D0|2000-08-30|

---

IL153726A|2008-07-08|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2000-07-11|Priority to GBGB0016876.5A

---

2000-07-11|Priority to GB0016876.5

---

2001-07-10|Application filed by 아스트라제네카 아베

---

2001-07-10|Priority to PCT/SE2001/001606

---

2003-03-28|Publication of KR20030025265A

优先权:

---

申请号 | 申请日 | 专利标题

---

GBGB0016876.5A|GB0016876D0|2000-07-11|2000-07-11|Novel formulation|

---

GB0016876.5|2000-07-11|

---

PCT/SE2001/001606|WO2002003958A1|2000-07-11|2001-07-10|Novel aerosol formulation containing a polar fluorinated molecule|